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PREFACE 
 
 
 
 “Why study bleeding in abdominal aortic aneurysm repair? Is the problem not already 
solved? We already know that bleeding in general is bad and leads to a worse outcome, and it 
is of course obvious that massive bleeding is life threatening!”  
“Do we really need to evaluate how we treat bleeding? Just transfuse the patient and stop the 
bleeding!” 
“In the era of endovascular repair bleeding in abdominal aortic aneurysm repair is no longer 
an issue!”  
 
-During this thesis project I have come across these questions and statements 
from colleagues and myself. Given the future lives that are at stake in the 
treatment of abdominal aortic aneurysms, the above questions demand firm 
answers. Hence the following…
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ABSTRACT 
Background and aims: 
Massive bleeding in open abdominal aortic aneurysm (AAA) repair is associated with worse 
outcome. However, few studies have investigated specific problems related to perioperative 
bleeding and blood transfusion in elective or emergent AAA repair with open (OR) or 
endovascular (EVAR) aneurysm repair. The overall aim of this thesis project was to 
investigate the clinical problem of bleeding in open and endovascular repair in both ruptured 
and elective AAA, including treatment of bleeding and association to risk factors and 
outcome in this patient group. 
Patients and Methods: 
The studies were retrospective and based on medical records (all) and regional and national 
registries (Papers II-IV). Paper I studied the Fascia Suture Technique (FST) as closure 
method for hemostasis in 160 femoral access sites after EVAR in AAA patients. Paper II 
investigated ruptured (rAAA) and non-rAAA cases undergoing EVAR in 525 patients. 
Perioperative bleeding and the association to mortality and morbidity was investigated. 
Paper III investigated preoperative coagulation tests and their association to preoperative 
hypotension and perioperative bleeding and outcome in 91 rAAA patients. Paper IV studied 
blood transfusion in 369 ruptured AAA (rAAA) patients undergoing OR or EVAR. Timing 
of blood transfusion and time dependent ratios of blood products were studied and related to 
method of repair and outcome.  
Results: 
In Paper I FST was associated with a 91% success rate. Complications were two 
pseudoaneurysms (PA) at 30-day follow-up and nine <1cm PA at 1-year. No specific 
preoperative risk factor for failure of the method was found. In Paper II a perioperative 
bleeding of >2 liters was independently associated with increased mortality (non-rAAA 
patients odds ratio 30; 95% CI [3.6, 145], rAAA patients odds ratio 10.7; 95% CI [3.2, 36.1]) 
and morbidity in non- and rAAA cases. Open femoral access, branched EVAR and larger 
diameter introducers were associated with increased perioperative blood loss.  In Paper III 
low preoperative fibrinogen concentration (<1.5 g/L) was significantly associated with 
preoperative hypotension (systolic blood pressure <70 mmHg), increased perioperative 
bleeding and worse outcome after rAAA. In Paper IV delayed platelet transfusion (>1h) was 
associated with increased mortality in rAAA patients requiring massive transfusion (>10 
units within 24 h or 4 units within 1 h). Fifty-five percent of rAAA patients repaired by 
EVAR received massive transfusion. Transfusion ratios of 1:1 for fresh frozen plasma 
(FFP):red blood cells (RBC) were associated with lower mortality. Ratios of platelets 
(PLT):RBC increased significantly over the study period. 
Conclusions:  
• Fascia Suture Technique proved feasible and safe with a low complication rate. 
Introducer size had no impact on outcome. No preoperative risk factors for failure were 
found.  
• A perioperative blood loss exceeding 2 liters in EVAR was independently associated 
with increased mortality and morbidity in both acute and elective AAA patients. 
Procedural risk factors for increased perioperative bleeding were open femoral access, 
fascia suture technique, branched stent grafts and aneurysm diameter. 
• Preoperative fibrinogen concentrations below 1.5 g/L were associated with a ten-fold 
increased risk of perioperative bleeding of more than 2 liters in rAAA. Low fibrinogen 
concentration should be suspected in patients with preoperative hypotension.  
• A ratio FFP: RBC close to 1:1 in EVAR and open repaired patients was associated with 
lower mortality.  
• Delayed (>1h) platelet transfusion was associated with significantly increased mortality. 
Ratios of PLT:RBC have increased over the last years.  
• Transfusion strategies in patients undergoing rAAA treatment with EVAR or open repair 
need further research. Also the definitive role of fibrinogen in patients with rAAA and 
hemodynamic shock need to be investigated in future studies.   
Keywords: Bleeding, Abdominal Aortic Aneurysm, Massive Transfusion, Hemostasis, 
Fascia Suture Technique, Endovascular Aortic Aneurysm Repair, Open Repair  
® Carl Montán, 2015 
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1 INTRODUCTION 
1.1 BACKGROUND 
Abdominal Aortic Aneurysm (AAA) is common in the aging population and ruptured AAA 
is a major cause of death. In open aortic surgery, massive blood loss is associated with 
increased mortality.1,2 In elective cases, AAA repair by open and endovascular methods are 
relatively safe procedures, but nevertheless associated with a high risk of perioperative 
bleeding. In emergencies from ruptured abdominal aortic aneurysm, massive bleeding is one 
of the toughest challenges a surgeon and his or her team can encounter where blood loss can 
be considerable before control is achieved.  
Bleeding in AAA repair has impact on both mortality and morbidity. Although extensive 
knowledge has been gained in the fields of hemostasis, coagulopathy and treatment of 
massive bleeding, few studies have focused on bleeding in AAA repair. Little is known about 
bleeding complications in the era of endovascular repair and risk factors for such 
complications are largely unknown. Transfusion strategies to manage bleeding in 
emergencies have evolved during the recent decades but few investigations have assessed the 
applicability to bleeding AAA patients. 
EVAR is an established method of treatment of infrarenal AAA.3 Blood loss in elective 
EVAR is most commonly a result of leakage from guide wire and sheath exchanges, and 
from complications during access site closure. The femoral access sites are the main concern 
for bleeding and previous studies have investigated perioperative bleeding related to closure 
devices and other methods of access site closure.4-7  
The purpose of this thesis has been to investigate key components of bleeding in AAA repair. 
The four scientific papers investigate practical issues, risk factors, and predictors of bleeding 
as well as the treatment of bleeding associated with both non-ruptured and ruptured AAA in 
open and endovascular repair.  
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1.2 HISTORICAL NOTES 
Arterial aneurysms were first described in the Eber Scrolls from Egypt in 1550 BC and in 
Sushruta from India 800-60 BC.8,9 Methods of treatment of Abdominal Aortic Aneurysms 
have included attempts to ligate the aorta first practiced by the Greek surgeon Antyllus 126-
216 AD.10 The method remained the preferred option up until the nineteenth century.11-13 
Inducing thrombosis of the aneurysm by wires was attempted by Moore and Murchison in 
1864.13 In 1948 Nissen and colleges wrapped the AAA of Albert Einstein with cellophane to 
induce a fibrotic process and hinder further expansion of the aneurysm.14 In 1951 Dubost 
performed the first AAA resection with restoration of arterial blood flow.15 Freeman reported 
the first successful resection and bypass of an AAA, using autologous vein in 1951.16 
Voorhees and Blakemore and Shumacker were first to describe the use of artificial grafts for 
AAA treatment in humans.17,18 
In 1986 a new method of endovascular repair was described by the Ukrainian surgeon 
Volodos, however it was not until the Argentinian surgeon Parodi described it in English in 
1991 that the method gained worldwide fame. 19,20 
It is believed that Plato (≈428-348 BC) first described the ability of blood to form fibers when 
outside the blood vessel.21 In 1865 platelets and their critical function in hemostasis were 
discovered.22,23 By the 1960’ many components in coagulation had been described and also 
the concept of the coagulation cascade or waterfall of events.24,25 In the last decades further 
knowledge has been gained in the very complex mechanisms of hemostasis.26  
The first blood transfusions are attributed to physicians Colle from Italy in 1628 and the 
Frenchman Denis in 1666.27,28 At the same time in England, Lower was one of the pioneers 
in the field of transfusion.29 Obstetrician Blundell understood that an incompatibility of 
human blood transfusion to some patients existed but could not explain why. Dr. Blundell 
performed successful human to human transfusions in 1825.30 However, it was not until Karl 
Landsteiner discovered the blood groups in 1900 and the Rh factor in 1940 that blood 
transfusions became safer.31 Blood transfusion has historically been controversial as it 
implies giving and accepting living cells from one or more donors. In some cultures and 
religions blood transfusions remain controversial.32 
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1.3 ABDOMINAL AORTIC ANEURYSMS 
1.3.1 Definition and pathogenesis 
An aneurysm is most commonly defined as a localized widening of all the layers (intima, 
media and adventitia) of the artery wall exceeding at least 50 % of the normal expected 
diameter.33 True aneurysms differ from vascular ecstasies that are described as a continuous 
non-localized enlargement of the diameter of the vessel. Pseudo-aneurysms, also referred to 
as false aneurysms, are defined as a circulated hematoma formed outside the arterial wall due 
to a defect in the artery, often formed after penetrating or blunt injury to the vessel. Dramatic 
deceleration forces can lead to substantial aortic injuries and rupture, often with deadly 
outcome.34 
Aneurysms can expand in a fusiform (includes the expansion of the whole circumference) or 
saccular (expansion of a partial circumference of the vascular wall) way.35,36 The etiology of 
saccular aneurysms have been suggested to be different to that of fusiform aneurysms often 
related to mycotic aneurysms (due to inflammatory or infectious events) or trauma.37  
Abdominal aortic aneurysms are defined as aneurysms below the anatomic landmark of the 
diaphragm. Aneurysms that include the aorta above the diaphragm are referred to as thoracic 
or thoracoabdominal if they include both the thoracic and abdominal parts. Thoracic aortic 
aneurysms are different from abdominal aortic aneurysms; possibly explained by 
biomechanical factors, differences in the origin of the smooth muscle cells and differences in 
the structure of the aortic wall (capillaries/vasa vasorum penetrate into the media in thoracic 
but not abdominal aorta). Abdominal aortic aneurysms can be described as infrarenal, 
juxtarenal or suprarenal. Suprarenal abdominal aneurysms could also be included in 
thoracoabdominal aortic aneurysms.38 
An abdominal aortic aneurysm is most commonly defined as a diameter expansion of the 
abdominal aorta exceeding 30 mm.39 The fundaments for this definition are based on the 
works by Steinberg and Stein in 1966 and Leopold in 1970.40,41 The definition is used in the 
UKSAT and ADAM trials.42,43 Sterpetti in 1987 defined infrarenal AAA as having a ratio of 
>1.5 calculated by the diameter of the infrarenal aorta divided by the diameter of the 
suprarenal aorta.44 Alternatively AAA can be defined as a 50 % dilatation of the expected 
normal artery diameter as described by Johnston et al. 1991, a definition used by the 
International Society for Cardiovascular Surgery.45 The ambiguous definitions of AAA have 
contributed to differences in epidemiology reports and clinical practice.46  
Aneurysms develop through a series of histopathological changes that lead to a weakening of 
the vascular wall. Inflammatory processes are thought to be key contributors to the 
histopathological changes.47-49 Inflammatory cells release proteolytic enzymes, which 
degrade elastin and collagen and promote apoptosis of smooth muscle cells in the media. This 
process affects the structural integrity of the vessel wall.50,51,52 In addition, the formation of a 
Carl Montán 
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mural thrombus in the dilated vessel segment has been shown to enhance structural 
deterioration of the underlying aortic wall, which promote aneurysm growth and risk of 
rupture.53  
Definitions below according to Rutherford.33 
1.3.1.1 Non-ruptured asymptomatic abdominal aortic aneurysm 
Non-ruptured asymptomatic AAAs are intact AAAs in patients without symptoms of pain or 
rupture by clinical examination and/or diagnostic imaging.  
1.3.1.2 Symptomatic abdominal aortic aneurysm 
Non-ruptured symptomatic AAAs are intact AAAs in patients with symptoms of abdominal, 
back or chest pain by medical history or clinical examination with tenderness over the 
aneurysm upon palpation. 
1.3.1.3 Ruptured abdominal aortic aneurysm  
Ruptured AAAs (rAAA) presents with signs of a rupture in the vascular wall leading to a 
hematoma outside the vascular wall. The rupture can be contained in the retroperitoneal space 
or be non-contained with massive intraperitoneal bleeding. The most common site of rupture 
is to the posterior left of the AAA.33 Ruptured AAA usually cause severe pain in the 
abdomen, back or chest. 
1.3.2 Epidemiology 
The epidemiology of AAA has been studied thoroughly through population based screening 
and necropsy studies.54-57 The prevalence of AAA among men 64-83 years was found to be 
4.0-7.6% in large randomized screening studies in the UK (Chichester 1995 and MASS 
2002), in Denmark 1998 and in Australia 2000 (extra data presented 2004).41,42,58,59,60 Recent 
Swedish reports from screening programs have suggested lower prevalence rates of 0.4%-
1.7%.61-63  
In women the prevalence of AAA is lower than for males. According to a Swedish study in 
2013 the prevalence was only 0.5% among 70 year old women.63 There are indications that 
women with AAA are more susceptible to rupture and have associated higher 30-day 
mortality rate after repair compared to males.64-66 
Independent risk factors for developing an AAA have been suggested by numerous 
authors.67-75 The most commonly described risk factors are; age, gender, height, family 
history of AAA, smoking, hypertension, coronary artery disease, hyperlipidemia, chronic and 
obstructive pulmonary disease. It should be noted that most studies are performed on white 
male Caucasians and that other ethnic groups have a different prevalence of AAA.67,76 
Symptomatic AAAs are reported to constitute 5.5%-22% of all AAAs that require repair.77-79  
Introduction 
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The incidence of rAAA varies in studies and increases significantly with age.80 In 1999 
Chosky et al. reported an incidence of 76 per 100,000 for men over 50 years and 11 per 
100,000 for women over 50 years.81 A report from Sweden 2006 describes incidences of 
AAA to be 10.6 per 100,000 over-all, 46 per 100,000 for males aged 60-69 and for males 70-
79 years the incidence was 117 per 100,000 patient years.80 
A thorough medical history and physical examination should be performed in order to assess 
risk prediction for repair of AAA. Multiple risk prediction models have been developed and 
proven to be useful in assessing risk for mortality and morbidity.82 Patients that are deemed 
with a high procedural risk might be suggested to abstain from repair. It has been suggested 
to develop different risk prediction models for OR and EVAR.82 
1.3.3 Diagnosis and imaging 
It is difficult to diagnose an asymptomatic AAA solely by clinical examination and medical 
history. An AAA can exist for many years without causing any clinical symptoms. Some 
patients experience a pulsation in the abdomen and AAAs can be diagnosed through 
palpation of a pulsating mass in the upper abdomen. It is however not a reliable method for 
diagnosis.83 Studies have shown ultrasound (US) to be a better method than palpation to 
diagnose AAA.83,84 Symptomatic and ruptured AAA usually gives symptoms as described 
above.33 AAA imaging through US, computed tomography (CT) or magnetic resonance 
imaging (MRI) has been compared.85 Ultrasound is not as sensitive as CT and MRI for AAA 
diagnosis especially in obese patients with proximal aneurysms. In Figure 1 three different 
techniques for the diagnosis of AAA are illustrated.  
 
Figure 1. Diagnosis of Abdominal Aortic Aneurysm by, palpation, ultrasound and computer tomography. 
Pictures used with the courtesy of the copyright holder. 
CT is the gold standard for measuring the diameter of AAA. The outer abdominal aortic wall 
is measured in cm and mm. CT is a very exact method in which the images are stored and can 
be used for planning in an eventual repair. However, CT is costly and overuse is potentially 
harmful as in might cause cancer.86 MRI is also an accurate method for measuring the aorta, 
but the method is not as accessible as CT and takes longer time to perform. MRI protocols for 
evaluating the morphology of the AAA and the intraluminal thrombus are being developed 
and evaluated.87,88 These methods might prove to be important for rupture prediction and 
better understanding of pathogenesis. 
The diameter of AAAs can also be measured by US. The main advantages of US are 
accessibility, and the use of non-harmful ultrasound waves. The disadvantages are 
Carl Montán 
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measurement variance between US users and that the diameter estimation is not as exact as 
CT.89 Three different ways of measuring diameter with US have been described and debated. 
See Figure 2. 
 
Figure 2. Techniques for measuring the diameter of the aorta by ultrasound 
The outer to outer diameter is said to resemble the measurements of CT most correctly and 
has gained wide international use.42 However, some argue that the posterior outer diameter 
often is difficult to visualize properly. Inner to inner diameter is a measurement that has been 
criticized by some as inaccurate, as too small diameters are measured especially if an 
intraluminal thrombus is mistakenly perceived as the inner wall. One comparative study and 
a review could not detect significant differences in inter-observer variability between 
different US measuring methods.90,91 Leading edge to leading edge is the method used in 
Swedish AAA screening programs.92,93  
In AAA surveillance programs, US has clear advantages over CT because of its accessibility. 
US has also been suggested as a valid method for postoperative follow-up to measure 
postoperative AAA diameter after EVAR after the first year CT control.94 
1.3.4 Indications for treatment 
1.3.4.1 AAA 
The indications for repair of AAAs have been debated over many years and an international 
variation still exists. According to large trials repair of AAAs is recommended for men at 
diameters above 5.5 cm and in women at 5 cm and above.95,96 Age and comorbidities such as 
cardiac and pulmonary disease, hypertension, previous stroke, tumor disease, and other 
chronic diseases are factors that influence life expectancy and needs consideration before 
deciding upon repair and repair method.82,97 
1.3.4.2 Symptomatic AAA 
Indications for repair of symptomatic AAAs are not based on diameter but on the symptoms, 
sometimes together with radiological findings. Abdominal and/or back pain together with a 
tenderness of the aneurysm upon palpation constitutes the symptoms.79 
1.3.4.3 Ruptured AAA 
In health care systems, the treatment of a rAAAs strains the organization to the maximum.98 
The time from rupture to treatment is one of the keys to success. Therefore, the primary 
Introduction 
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action should always be to care for the patient as if repair was to be performed as quickly as 
possible. Untreated rAAAs almost always leads to the death of the patient. However, the 
indication to repair a rAAA also requires an active decision that the procedure is beneficial to 
the patient.97 In general, treatment is not controversial, but some elderly patients or patients 
with serious comorbidities with known AAA or unknown AAA may reject treatment in case 
of a life threatening event and decisions should be anchored with the patient and close 
relatives if possible. There are patients who survive a rupture without surgical treatment for 
many years. 
1.3.5 Treatment of AAA 
1.3.5.1 Open repair 
Open repair is most commonly carried out through a midline abdominal incision and a 
transperitoneal approach. The retroperitoneum is incised and the structures overlaying the 
aorta are carefully dissected. After proximal and distal control of the aorta and its branches 
where the vascular wall is free from aneurysm, the aorta is opened in a longitudinal fashion. 
Back bleeding lumbar arteries and the inferior mesenteric artery (IMA) are over sewn (if 
indicated). A synthetic straight or bifurcated graft of appropriate size is then is sewn into the 
aorta and its branches as appropriate by continuous sutures of 3-0 Prolene or similar suture 
material. See Figure 3. The surgery is performed under general anesthesia. The operating 
time varies greatly depending on the anatomical position of the aneurysm and other factors. A 
retroperitoneal approach by a left subcostal transverse incision is often suggested for open 
surgery of AAA where a supra renal or supra coeliac clamping is required. It has by some 
authors been shown to be associated with less perioperative bleeding.99  
 
Figure 3. Open surgery of an abdominal aortic aneurysm, in the picture to the right a bifurcated graft has been 
sewn into the aorta. Pictures used with the courtesy of the copyright holder. 
1.3.5.2 Endovascular repair 
EVAR can be performed under general or local anesthesia.100 The endovascular graft can be 
bifurcated or a uni-iliac. A bifurcated reconstruction is normally the preferred choice. In the 
setting of preoperative unilateral iliac obstruction, a uni-iliac stent graft is an option. In the 
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case of acute rupture without adequate possible sizing of a bifurcated graft a uni-iliac stent 
graft can be used. A femoral-femoral bypass should then also be performed to maintain blood 
flow to the contralateral leg. There are now many different manufacturers of stentgrafts 
approved for the reconstruction of AAA and care should be taken in selecting the most 
suitable for the individual patient.101,102 
Before the procedure, a careful planning is required in selecting the appropriate stent graft for 
the anatomy, status and physiology of the patient. CT angiography (CTA), with thin (<1 mm) 
slices and image reconstruction in several planes, is the preferred diagnostic method to plan 
the procedure and make necessary measurements.101 See Figure 4. 
 
Figure 4. (Left to right) Computer tomography angiography (CTA) with 3D reconstruction of an abdominal 
aortic aneurysm, aortic angiogram under the endovascular aortic aneurysm repair procedure followed by CTA 
3D reconstruction of stent graft in place. Pictures used with the courtesy of copyright holder. 
The synthetic aortic stentgraft is delivered into the aorta and iliac arteries by pre-packed 
introducer devices of various sorts. The main body is usually delivered through one of the 
femoral arteries that is chosen to be the ipsilateral side.  
Access to the common femoral arteries can be performed by percutaneous puncture using the 
Seldinger technique.103 The percutaneous puncture is preferably made under guidance of 
ultrasound or X-ray.104,105,106 The aim should be to enter the femoral artery in the mid section 
between the epigastric artery and the bifurcation. A puncture on the most frontal part of the 
artery’s circumference should be attempted.104,106 Access to the femoral arteries can also be 
performed through open surgical exposure.  
Via the contralateral femoral artery, the distal stent graft of the contralateral side is delivered. 
The recommended measurements for the proximal and distal sealing zones as well as for the 
overlap between contralateral stent graft and elongation stent grafts on the ipsilateral side 
differ between stent grafts.102 A completion angiography is performed to ensure the correct 
placement of the device, without stenosis or kinking and proximal and distal sealing without 
endoleakage. Special care is taken to visualize the coeliac trunk, renal-, superior mesenteric-, 
and internal iliac arteries to make sure that they are patent. 
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After the procedure, closure of the femoral and/or other access sites is performed using open 
surgical exposure (cut down), suture mediated closure devices or fascia suture technique.  
The closure device most commonly used and described in literature is the ProStarXL® (for 
large diameter access double devices are used). This technique is performed by deploying 
sutures in the vascular wall at the puncture site via a special device in the beginning of the 
EVAR procedure. In the end of the procedure the sutures are tied together to obtain 
hemostasis. The technique is referred to as the preclose technique.107,108 
In case of postoperative minor bleeding a device called FemoStop® can be applied for 
hemostasis.106,109 The FemoStop® holds pressure on top of the femoral access site in order for 
the puncture hole to seal. Postoperatively the distal pulses should be controlled in order to 
assure that no iatrogenic injury or thrombosis has occurred. 
1.3.6 Outcome AAA treatment 
Due to the severity and complexity of the diagnosis of AAA a relatively high risk of mortality 
and morbidity is associated also with elective AAA repair. The mortality and morbidity risks 
are obviously incomparably much higher in rAAA repair compared to elective repair. 
Symptomatic AAAs are associated with higher risk of morbidity and mortality compared to 
elective AAA repair, probably explained by the pre-rupture status that is suspected in 
symptomatic AAAs.77,79 
The outcomes of OR and EVAR for AAA have been extensively studied in different trials. 
The most well known randomized trials are the UK Endovascular Aneurysm Repair 1 
(EVAR-1) trial, the Dutch Randomized Endovascular Aneurysm Management (DREAM) 
trial and the Open versus Endovascular (OVER) trial, described below.110-112 There is still no 
clear scientific evidence that favors long-term outcome results of one method over the 
other.113 An advantage for EVAR compared to OR has been suggested in the latest trials, 
especially in rAAA. However criticism has been raised towards design and patient selection 
in these trials.113 Theoretically EVAR could be advantageous in the rAAA patient group with 
hemodynamic and physiologic impairment as it is minimally invasive and can often be 
performed under local anesthesia.114 
Several factors contribute to the outcome of repair for AAA. Age, comorbidity and medical 
history, ongoing and previous smoking, physical fitness and the anatomic complexity and 
morphology have been suggested as important factors for the outcome. The AAA 
morphology has been studied on CT and MRI and attempts have been made to suggest 
protocols for three-dimensional evaluation, however no consensus has been reached of how 
morphology relates to outcome.115  
1.3.6.1 Elective Abdominal Aortic Aneurysms  
Clinical trials evaluating outcome of AAA repair over the last 10 years have mostly focused 
on comparing EVAR to OR. In 2005 the EVAR-1 trial from UK compared OR to EVAR for 
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the treatment of AAA.116 A study from the Netherlands (DREAM trial) also presented a 
comparison between OR and EVAR.117 In 2009 the results from the OVER study from the 
USA presented their results comparing the two methods.118 The French ACE trial reported a 
comparison in 2011.119 A meta-analysis from 2013 included the above studies together with 
material from the Swedish Vascular registry and the Medicare registry from the USA to 
analyze short- and long-term outcome. There was an overall short-term survival advantage 
(30-day mortality) in patients treated with EVAR (EVAR 1.3% vs. OR 4.7%). The long-term 
survival in comparing the two methods showed no statistical difference. In the EVAR group 
fewer myocardial infarctions (MI) were seen, but this group instead had more re-
interventions and ruptures. The rate of renal insufficiency and stroke were similar in the 
RCTs.120 
1.3.6.2 Symptomatic Abdominal Aortic Aneurysms 
Mortality rates for symptomatic AAAs have been ranging from 4-22%. Morbidity in the 
symptomatic AAA is also higher than normal elective AAA repairs. 77,78,121,122 The reasons 
for this are unknown but several factors probably contribute. The pre-rupture status has been 
mentioned as a strong contributing factor but does probably not fully explain the increased 
risks. Most of the deaths after repair of symptomatic AAA repair have been attributed to 
cardiac complications.123 Morbidity has also been reported to be high and includes MI, 
stroke, respiratory and renal failure.124 It has been suggested that unknown heart disease is 
more common in patients presenting with symptomatic or ruptured AAA than in elective 
AAA patients and hence without comparable cardio-protective therapy such as aspirin, beta-
blockers and statins. This could contribute to increased risk.123,125,126 
1.3.6.3 Ruptured Abdominal Aortic Aneurysms   
Ruptured AAAs are associated with dramatic presentations with possible hemodynamic 
shock, coagulopathy and associated high risk of mortality and morbidity. The associated 
mortality rates after rAAA repair have been reported to range from 20% to 50%.77,113,127-129 
The most common complications reported are: respiratory failure, multi organ failure (MOF), 
MI, renal insufficiency, abdominal compartment syndrome (ACS), leg ischemia and bowel 
ischemia.77,130 Reduced mortality has been suggested to be associated with increased use of 
EVAR in high volume, teaching centers and weekday admission according to a study that 
compared outcome in USA and UK.131  
Three RCTs (Nottingham, AJAX, and IMPROVE) have compared the outcome of OR vs. 
EVAR in patients with rAAA.132-134 The studies failed to show any significant difference in 
30-day mortality [OR vs. EVAR; 53% vs. 53%, 25% vs. 21%, and 37 vs. 35% respectively]. 
Data from the RCTs on blood loss and transfusion are presented in section 2.7. 
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1.4 HEMOSTASIS 
A basic understanding of hemostasis is fundamental in bleeding research. The hemostatic 
process is key to find new methods to tackle the potential dangers of bleeding in AAA repair. 
1.4.1 Definition 
The process of hemostasis acts as the bodies’ defense mechanism against hemorrhage. The 
body has a remarkable ability to control bleeding if it occurs, given that it is not too 
extensive. Hemostasis is usually divided into primary and secondary hemostasis. It also 
includes the regulation of hemostasis. The processes occur at the same time and together. In 
primary hemostasis, vasoconstriction and platelet aggregation take place. In secondary 
hemostasis the blood coagulation system is activated. The regulatory mechanisms of 
hemostasis by fibrinolysis and other inhibitory systems are essential for the clot formation to 
occur at the right location in the body and to the appropriate extent. 
1.4.2 The hemostatic process 
1.4.2.1 Primary hemostasis 
The endothelial cells in the vascular wall take part in regulation of the vascular tone. In the 
case of injury the smaller arteries constricts in order to divert blood from the damaged area. 
This is mediated by the release of vasoactive proteins from the damaged endothelial cells and 
from thromboxane A2 (TXA2) and serotonin released by activated platelets.  
The extracellular matrix (ECM) in the subendothelial layer contains the highly reactive 
proteins collagen and von Willebrand factor (vWF). In the case of damage the exposed 
collagen and vWF bind to and activates the platelets and they start to stick to and roll on the 
vascular wall by adhesion. Eventually they slow down and stop and the platelets bind to each 
other causing aggregation and a platelet plug is formed.  
When platelets are bound by their receptors to the ECM, thrombin will be generated and 
granules in the platelets will release adenosine diphosphate (ADP) and TXA2. When platelets 
are activated and adhere to each other and the ECM, they change from their discoid shape to 
become spherical with dendritic structures protruding out from the body. This structural 
change together with activation of fibrinogen helps the aggregation.  
The primary platelet aggregation is not stable enough on its own. It needs the fibrin matrix 
produced by the process of blood coagulation in order to firmly stabilize the clot. The initial 
thrombus formation of aggregated platelets will generate a phosphatidylserine-exposing 
membrane surface, which will cause the formation of tenase and prothrombinase complexes 
and activated coagulation factors.135-138 Figure 5 describes the most important steps of 
platelet function in hemostasis. 
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Figure 5. Platelet activation, adhesion and aggregation. The stages of platelet activation and thrombus 
formation. ”Platelets adhere to von Willebrand factor (vWF)/collagen matrix, get activated, secrete granular 
contents, aggregate via integrins, produce thrombin after developing a procoagulant surface, and form a 
contracted thrombus with fibrin. Heat map with color codes from green (low Ca2+ signal) to red (high Ca2+ 
signal). Procoagulant platelets provide a phosphatidylserine (PS)-exposing surface for the tenase complex 
(activated FVIII and FIX) and the prothrombinase complex (activated FV and FX). Formed thrombin 
provides positive-feedback” From Versteeg et al.21 Used with permission from the publisher. 
1.4.2.2 Secondary hemostasis 
The process of coagulation is a complex set of events with activators and inhibitors that have 
been elucidated by many authors.21,26 It is often described as a set of chain reactions 
(frequently referred to as a cascade) and propagation loops where also positive and negative 
feedback loops play important parts. The aim of the coagulation process is to form enough 
fibrin matrix to form a strong and stable clot and heal the vascular wall.21 
The coagulation cascade is initiated by TF released from fibroblasts, macrophages and 
endothelial cells after injury to the vessel wall. TF binds to activated FVII (FVIIa), which 
activates FIX and FX into FIXa and FXa. FXa activates FV and forms a complex 
(prothrombinase). These FXa/FVa complexes bind to TF and start to convert prothrombin to 
thrombin.21 
Thrombin amplifies the coagulation process by activating more FV into FVa, FVIII into 
FVIIIa and FXI into FXIa. The platelets are hence further activated. 
On the activated platelet complexes of FIXa/FVIIIa (tenase complex) and FXa/FVa  
propagates the coagulation further by converting masses of prothrombin into thrombin. The 
thrombin splits fibrinogen into fibrin monomers, which form the stable fibrin mesh together 
with the activated platelets.21 The above mechanisms are briefly illustrated in Figure 6. The 
fibrin mesh is visualized in Figure 7. 
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Figure 6. The coagulation cascade. “Upon endothelial damage, tissue factor (TF) is exposed to the 
bloodstream and binds factor VII, which is activated to factor VIIa. The TF:VIIa complex enables 
subsequent activation of factor X and prothrombin, after which small amounts of thrombin activate 
the factor XI-IX feedback loop on the platelet surface. Factor IXa will then activate additional 
factor X. Simultaneously, the trace amounts of thrombin will then activate factors VIII (cofactor to 
factor IX) and V (cofactor to factor X), which dramatically enhances catalytic activity of factors IX 
and X. Finally, thrombin (factor IIa) activation leads to fibrin deposition. In parallel, local 
polyphosphate (polyP) release by activated platelets may additionally stimulate activation of factor 
XII, factor V, and FXI and inhibit clot lysis.” From Versteeg et al.21 Used with permission from the 
publisher. 
 
 
 
 
Figure 7. Red blood cells trapped in fibrin 
threads. A stable fibrin mesh is formed. Thrombin 
(FII) converts Fibrinogen into Fibrin. The Fibrin 
form stable strands between the platelets and the 
other blood cells as demonstrated by the electron 
microscope picture. "red blood cell: red blood 
cells trapped by fibrin threads". Photograph. 
Encyclopædia Britannica Online. Web. 16 apr. 
2015 Open access, with permission. 
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1.4.3 Regulation of hemostasis  
The inhibitory regulation of coagulation by fibrinolysis and other mechanisms control the 
coagulation process and stop it when the goal of hemostasis is reached. These mechanisms 
are important contributors to the success of the coagulation system.26 
The inhibition is mediated by inhibitory enzymes and by modulation of the functions of the 
coagulation factors. The most important inhibitory enzymes are antithrombin, protein C and 
tissue factor pathway inhibitor (TFPI). In the normal vascular wall prostacyclin (PGI2) and 
nitric oxide (NO) prevent platelet activation and aggregation.  
Antithrombin is present in normal blood and inhibits several of the coagulation process’ free 
enzymes thereby limiting the coagulation process to the site of injury. Protein C is activated 
into activated protein C (APC) by thrombin binding to thrombomodulin, a receptor on the 
endothelial cell. APC and it cofactor, protein S, inactivate FVa and FVIIa thereby 
significantly decreasing the production of thrombin. Tissue factor pathway inhibitor (TFPI) 
regulates the initiation of the coagulation system by effectively inhibiting the TF/FVIIa 
complexes and FXa. This shuts down the initial phase of plasma coagulation. 
Fibrinolysis refers to the process of fibrin breakdown. Fibrinolysis is mediated through the 
conversion of plasminogen to plasmin by enzyme activators, tissue plasminogen activator (t-
PA) and urokinase plasminogen activator (u-PA). This process takes place after circulating 
plasminogen binds to a fibrin clot. T-PA is the most important of the plasminogen activators 
and is itself inhibited by plasminogen activator inhibitor-1 (PAI-1) and PAI-2, activated 
thrombin activatable fibrinolysis inhibitor (TAFIa) and alfa2-Antiplasmin.139   
1.4.4 Effect of bleeding on hemostasis 
Bleeding and vascular injury is the trigger of hemostasis. Large volume bleedings left 
untreated empties the supplies of blood cells and coagulation factors and leads to hampered 
hemostasis. Vasoconstriction compensates for the lost blood volume but implies also the loss 
of peripheral temperature control, which in turn eventually leads to a lower central 
temperature, and decreased ability of the hemostatic process to function.140 
1.4.5 Coagulopathy 
1.4.5.1 Definition 
Coagulopathy is defined as impaired hemostasis.141 No general consensus exist for laboratory 
threshold values or limits for impairment to define coagulopathy. Some authors also describe 
coagulopathy as a hypercoagulable and thrombotic state.141 In the following text 
coagulopathy is referred to as a defect ability to form a stable clot. It can be acquired by 
heavy bleeding, sepsis, trauma, hypothermia (<36.5oC), dilution, disease, narcotics use or 
through medication. Hemostatic disorders can also be inherited such as von Willebrand 
disease, coagulation factor or platelet disorders. Coagulopathy can lead to uncontrollable 
bleeding and if not properly treated it is associated with a significant risk of mortality.141,142 
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1.4.5.2 Pathophysiology 
Coagulopathy can develop either through deficiency or malfunction of platelets and 
coagulation factors, activators and enzymes. It can also develop due to an altered 
environment in which the hemostatic process does not function properly, such as 
hypothermia, acidosis, insufficient number of RBC (<90g/L) and low ionized Calcium (Ca2+). 
Also the use of medications can alter coagulation and platelet function.141 
Coagulopathy has been described to develop during lengthy surgery procedures, probably due 
to fibrinolytic activation, dilution, altered environment (as above) and unknown stress-related 
effects.142 
Trauma induced coagulopathy (TIC) or Acute Traumatic Coagulopathy (ATC) has been 
described as the rapidly observed malfunctioning of coagulation after major trauma.143,144 
Threshold values for coagulopathy of PTr-INR >1.2 and APTT >35 s have been suggestive 
of coagulopathy.145,146 The role of viscoelastic testing (TEG/ROTEM) for developing new 
definitions is under way.147 
1.4.6 Medical drugs that alter hemostasis  
A vast number of medical drugs have been developed to modify the coagulation process in 
order to avoid thromboembolic events that can lead to stroke or myocardial infarctions. 
Anticoagulants can be organized according to the inhibitory effect by which they act or by 
their molecular similarity. 
Vitamin-K-antagonists (Warfarin) and Heparin, low molecular weight heparin (LMWH) and 
the new oral anticoagulants (NOACs) acts on the coagulation system by inhibiting different 
coagulation factors or feedback loops. These medications are given to inhibit thrombosis 
formation. Enzymes such as Alteplase and Streptokinase are used to enhance the fibrinolysis 
and dissolve a formed thrombus.  
Antiplatelet drugs are among the most commonly prescribed medicines due to their protective 
effects for myocardial infarction. The most common antiplatelet drugs are Acetylsalicylic 
Acid (ASA), Clopidogrel, Prasugrel and Ticagrelol. ASA inhibits COX-1 from binding to 
TXA2 receptor whereas Clopidogrel, Prasugrel and Ticagrelol inhibit the ADP-P2Y12 
receptor on the platelets. The even more aggressive platelet inhibitory drugs Acciximab, 
Tirofiban and Eptifbatide are GPIIb/IIIa receptor inhibitors.148 
Also other medications, such as steroids (prednisolone, cortisone), non-steroid anti-
inflammatory drugs (NSAID) (ibuprofen, diklofenac) and anti-depressive serotonin inhibitors 
are known to interfere with coagulation and increase risk of bleeding.149 
1.4.7 Measuring hemostasis 
The functionality of the hemostatic process can be measured by a number of different 
laboratory tests and methods presented in Table 1. 
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Table 1. Tests for hemostasis 
 
Test name and units Method Description of test Reference interval 
Platelet concentration 
(109/L) 
Platelet count by 
automated impedance 
or flow-cytometric 
quantification  
Measures the platelet 
number but not function 
125-400 (109/L) 
Activated partial thrombin 
time APTT (s) 
Clotting time in plasma 
after adding reactant 
Activity of factors II, V, 
VII, IX, X, XI, XII and 
fibrinogen, usually used 
for measuring affect of 
heparins 
30-40 s (depends on the 
type of the reactants used, 
no international standard 
exists) 
Anti-FXa activity Specific calibration to 
each of medications 
tested 
Concentration of heparin 
and LMWH, rivaroxaban 
apixaban, fondaparinux 
According to local 
laboratory 
Prothrombin time ratio-
International Normalized 
Ratio PTr-INR (ratio) 
Coagulation time 
Measured in reactant 
(thromboplastin, FV 
and fibrinogen) only 
measuring K-vitamin 
dependent F II, VII and 
X 
Warfarin effect test 
standardized by relating 
local protrombin time to 
international standard  
<1.2 (normal). The 
suggested therapeutic 
interval for patients on 
warfarin is usually 
suggested to (2.0-3.0).  
Prothrombin time PT (s) Time for plasma to 
form a clot after 
addition of TF 
High variance therefore 
replaced by PTr-INR 
11 - 13.5 s 
Activated clotting time 
ACT (s) 
Time for clot to form in 
whole blood after 
adding FXII activators 
Affected by several 
factors, normally used as 
bedside test of heparin 
effect as it is very quick 
107 ± 13 s 
Fibrinogen (g/L) Clauss method 
Adding excess amount 
of thrombin 
Estimates Fibrinogen 
concentration 
>2-4 g/L 
P-Antithrombin (units 
depend on test method) 
Measures heparin 
cofactor activity, 
different techniques are 
available 
Low values are seen in 
massive bleeding due to 
consumption of 
coagulation factors and in 
liver deficiency and long 
term Heparin use 
80 - 120 % of expected 
value 
TEG and ROTEM  Clot formation 
activation by Kaolin or 
TF 
Thromboelastogram 
acquired by clot 
formation time and 
strength and durability by 
mechanic evaluation 
See Figure 8  
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Different platelet function 
test; Multiplate, 
VerifyNow, PFA-100148 
Analysis of platelet 
function by assessing 
receptor reactance in a 
variety of methods 
Platelet function testing   
pH Assessing acidity    >7.2 
Ca2+ (mmol/L) Concentration of 
Ionized Calcium by 
using an ion selective 
potentiometric 
electrode  
Ionized Calcium is the 
most secure form of 
measuring active 
Calcium concentration in 
blood 
1.14 – 1.32 
Temp (oC) Central body 
temperature should be 
used 
Low body temperature 
impair hemostasis 
>36.5 
 
A brief description of viscoelastic tests of hemostasis is presented in Figure 8. 
 
Figure 8. A sample trace of the viscoelastic tests of TEG and ROTEM is demonstrated; R/CT 
(reaction/clotting time) measures the speed to reach a specific level of clot strength, α  -measures the 
rate of clot formation and reflects the rate of fibrin build up, MA/MCF (maximum 
amplitude/maximum clot firmness) represents the strength of the clot (platelets & fibrin) function of 
maximum dynamic properties of fibrin & platelet bonding via GPIIb/IIIa receptors LY 30/CLI (lysis 
at 30 minutes as ratio of MA/clot lysis index) measures clot stability by rate of amplitude reduction 
from MA at 30 minutes, detects fibrinolysis.150 Used with permission from the publisher (Open Access 
article).151 
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1.5 BLEEDING 
Surgical bleeding can be referred to as either perioperative or postoperative bleeding. In this 
thesis perioperative bleeding is the main focus. Other types of bleeding can occur, induced by 
medical drugs altering the hemostasis balance, due to disease, trauma or 
unknown/spontaneous bleeding. The specific considerations related to bleeding in AAA will 
be described in section 1.7.    
1.5.1 Monitoring and measuring bleeding 
It is difficult to accurately measure perioperative blood loss. Literature describes that the 
surgeon often underestimates the blood loss. Therefore the anesthesiologist in charge often 
estimates the blood loss by adding several factors.152 First the blood collected in operative 
gauzes and suction from the wound is measured. To this is added an estimation of the 
bleeding volume based on resuscitation and transfusion requirements, hemodynamic status 
and hemoglobin. It is argued in the literature that the patients’ normal physiology and 
estimated total blood volume should also be taken into account when calculating 
perioperative blood loss. Formulas for calculating perioperative blood loss have been 
suggested.152 
1.5.2 Patient reactions to bleeding 
Patients react to perioperative bleedings differently according to preoperative physiologic 
status such as previous cardiovascular diseases, and general health and fitness. The 
magnitude of bleeding will affect the patient in different ways. The classification described 
by Baskett of bleeding volumes related to the patients estimated blood volume is widely used 
in trauma literature.153,154 It describes how different bleeding volumes, in healthy young 
males, in trauma, influence the hemodynamic status. The clinical relevance of this 
classification has however not been analyzed. The applicability of this classification in other 
settings than trauma can also be questioned. In the papers presented in this thesis we have not 
used this classification. It is included here for completeness of background and as a reference 
for the hemodynamic changes observed and related to bleeding. The volumes described 
below are related to an estimated blood volume (EBV) 5000 ml (as such of a 70 kg healthy 
male). 
Stage I.  Loss of < 15% of the EBV (<750 ml)   
 No physiologic changes observed. Vasoconstriction maintains the blood 
pressure.  
Stage II.  Loss of 15-30% of the EBV (750-1500 ml)  
 Patients react with tachycardia and possibly with a slight decrease in blood 
pressure. Blood flow is reduced to skin, muscles and abdominal organs, while 
the circulation to the heart and brain is maintained. 
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Stage III.  Loss of 30-40% of EBV (1500 – 2000 ml) 
 Tachycardia and tachypnea compensates for a decreased cardiac stroke volume 
but normal circulation cannot be maintained and a significant reduction of 
blood pressure is observed. The patient is usually mentally affected. 
Stage IV.  Loss of >40% of EBV (>2000 ml)   
 A significant increased risk for irreversible shock and death is observed if not 
the patient is resuscitated immediately. Blood loss of >50% EBV often results 
in unconsciousness and severe hypotension. 
1.5.3 Treatment of bleeding  
The treatment of bleeding, other than stopping it surgically, is constituted of blood volume 
replacement by intravenous fluids and blood transfusion. Intravenous fluids such as 
Crystalloids are given according to local protocol. If blood transfusion is necessary, Red 
Blood Cells (RBC) are given first and if the bleeding is significant, Plasma and Platelets are 
also transfused. A number of other measures can also be added to the treatment. If needed the 
patient is rewarmed, pursuing a temperature above 36,5 degrees Celsius, and by tribonate 
infusion a normal pH level is aimed for, as the coagulation system does not function properly 
in hypothermia and acidosis (pH <7,2). Extra coagulation factors, apart from the ones 
included in the transfusion of plasma, can be administered. Also other procoagulatory 
substances such as vWF and FVIII enhancers, Calcium and antifibrinolytic substances such 
as Tranexamic acid are frequently given in substantial bleeding.155,156 Cardiac stimulating and 
vasoactive drugs such as norepinephrine are also used if blood pressure deteriorates.  
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1.6 BLOOD TRANSFUSION 
A number of inherent problems with blood transfusion must be overcome in order to 
minimize risks of serious complications. Blood is composed of plasma and blood cells. The 
red blood cells transport oxygen and carbon dioxide to and from the cells of the body. The 
white blood cells are important in the defense against infection and in inflammation. The 
platelets are the smallest blood cells and have numerous functions as mediators and as active 
participants in hemostasis and wound healing. Plasma contains much of the vital proteins. 
The coagulation factors are present in plasma.  
The A and B antigens on the surface of the red blood cells and the anti-A and anti-B 
antibodies in plasma are the main obstacles to blood transfusion causing aggressive reactions 
if blood is transfused to a non-compatible blood group. The four blood groups A, B, AB and 
O are based on these antigens and antibodies. The Rhesus group system divides persons who 
are D-antigen carriers into positive (+) present and those without D-antigen as negative (-) 
absent. There are also minor systems for controlling compatibility of blood groups based on 
the presence of other antibodies (eg. Kell). Computerized and/or serological cross-matches 
should be performed before transfusion is initiated. In case of emergency when there is no 
time for cross matching only O(-) blood is transfused as this blood group can be universally 
donated. 
Much of todays knowledge and practice of massive transfusion including the use of protocols 
are derived from the trauma literature.157 
1.6.1 Definition 
Blood transfusion is defined as administration of blood components from one or more donors 
into the blood system of another patient. The compatibility of the donor vs. receiver must be 
known. Autotransfusion is defined as a process where a patient is transfused with his or her 
own blood.  
1.6.2 Blood products 
Transfusion of whole blood has again gained interest in combat zones from one warrior to 
another as a means of effectively using resources and decreasing the demands for advanced 
forms of collecting, storing and preparing blood products in remote areas.158 The use of 
whole blood also has theoretical advantages compared the use of processed blood products 
described below. In order to make it possible to store and safely administer blood, it is usually 
collected and prepared by rigorously controlled methods.159 
Blood is collected and separated into units to be able to administer the products on demand i.e 
RBC for anemia, PLT to patients with thrombocytopenia and plasma to patients suffering 
from liver disease. In the case of substantial bleeding all of the components are required to 
replace the blood loss.   
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1.6.2.1 Red blood cells 
In Sweden packed red blood cells are collected and stored in units of 210-300 ml containing 
red blood cells 120-200 ml, plasma 10-20 ml and nutritional solution (usually SAGMAN; 
Saline, Adenine, Glucose and Mannitol) ≈100 ml. The units can be stored for up to 35-42 
days in 2-6 o C. The RBCs are usually filtered for leucocytes.  
1.6.2.2 Plasma 
Plasma is prepared and stored in units of 210-280 ml. Fresh plasma can be stored in 2-6 o C 
for up to 14 days if coagulation factors VIII and V are reduced. Fresh frozen plasma (FFP) is 
frozen 8-18 h after collection and contains 70% of the normal amount of coagulation factors. 
One unit is prepared from a single donor. It takes about 30-45 minutes to thaw a unit of 
plasma. Thawed FFP is good for use for up to 5 days after thawing. In Sweden plasma from 
males only are used in order to avoid Transfusion Related Acute Lung Injury (TRALI).159,160 
1.6.2.3 Platelets   
In Sweden one unit of platelets contains >240 x 109 platelets extracted from 4-6 donors by 
centrifugation or apheresis. The platelets are suspended into 350 ml nutritional solution and 
leucocyte reduced plasma. The packed units of platelets are stored at 22 o C under continuous 
gentle agitation in plasticized bags for up to five days. In many other countries platelets are 
prepared and stored in units from a single donor. This implies that units of platelets referred 
to in international literature are composed of approximately 1/4th of the Swedish units. 
1.6.3 Massive Transfusion 
1.6.3.1 Definition 
The most common definition of massive transfusion (MT) is transfusion of ≥10 units of RBC 
in 24 h.161 Alternative definitions are ≥4 u of RBC within 1 h and transfusion of 50% of the 
estimated blood volume in 3 h.157 It might be argued that the former two definitions are 
advantageous because of the lesser timespan that has to be reached before declaring massive 
transfusion. However the first definition is by far the most widely used in the literature.157 
1.6.3.2 Massive transfusion protocol 
Most emergency hospitals nowadays have a massive transfusion protocol (MTP). It should be 
well known and implemented as standard practice for the treatment of massively bleeding 
patients. The transfusion routines, including blood product ratios (RBC:FFP:PLT), should be 
stated in the MTP. It should also include the indications for use of pro-coagulatory drugs (i.e 
Fibrinogen and Tranexamic acid), Calcium and in need Tribonate. The MTP usually also 
includes suggested intervals and target values for blood chemistry analysis, temperature and 
blood pressure.157,162 
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1.6.3.3 Autotransfusion 
Autotransfusion is used as a method of perioperative blood salvage by collecting shed blood 
during surgery by suction into a device (e.g. Cell Saver® or other) and then giving it back to 
the patient. In the process of collection the automated system withdraws most of the plasma 
and platelets from the blood given back. By depletion of coagulation factors the 
autotransfused blood has lower risk of initiating an unwanted coagulation process. 
Blood can also be collected from the patient in advance of a surgical procedure or treatment 
and stored and given back to the patient by transfusion if needed. 
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1.7 HEMOSTASIS, BLEEDING, COAGULOPATHY AND 
TRANSFUSION IN AAA  
The repair of elective, symptomatic and ruptured AAA addresses special aspects on bleeding, 
hemostasis, coagulopathy and blood transfusion. The method of repair (OR or EVAR) 
impacts the way to approach these problems.  
AAA disease itself may affect the hemostatic process.163 The AAA patient might be on 
medications, which interfere with the hemostasis. In ruptured AAA, coagulopathy is reported 
to develop early. 
Bleeding in aortic repair can be substantial and the surgical team including the 
anesthesiologist, coagulation laboratory and the blood bank must have a prepared strategy to 
deal with massive bleeding in these cases. 
1.7.1 Hemostasis in AAA  
1.7.1.1 AAA and hemostasis 
Hypercoagulability has been suggested as a reason for thrombus formation in the vascular 
wall of an aortic aneurysm.117 It has been shown that patients with AAA have increased 
levels of fibrinogen, which might be a result of an ongoing inflammatory process.164,165 This 
might contribute to the activation of the coagulation. Hyperfibrinolysis and increased 
proteolytic activity have also been observed.163 The formation of intraluminal thrombus at the 
site of the AAA has also been suggested to depend upon platelet activation and shear 
stress.166,167 A recent meta-analysis showed increased levels of fibrinogen, D-dimer and 
thrombin-antithrombin III complexes in plasma of AAA patients.163 
The risk of increased bleeding is one aspect of a malfunctioning hemostatic equilibrium in 
AAA repair. Perioperative and postoperative thrombus formation is another, sometimes with 
high morbidity and mortality as a consequence.168 
Additional studies are needed in order to answer if AAA is associated with imposed 
hypercoagulability or an inherent susceptibility to coagulopathy.  
1.7.1.2 Coagulopathy in AAA 
As stated above, many times coagulopathy develops early after rAAA and derangements in 
fibrinogen, PTr-INR, APTT and platelet count are frequently observed.169-172 The exact 
frequency of coagulopathy in elective AAA repair is unknown and depends on the definition. 
Studies suggest that coagulopathy develops in rAAA patients because of the massive 
bleeding and the inflammatory response.171-174 
The existing definition of coagulopathy as malfunctioning hemostasis is very broad and 
therefore offers limited applicability in suggestions for treatment to correct coagulopathy. In 
AAA a detailed approach must guide the actions to be taken in order to correct the problems.  
Carl Montán 
32 
Transfusion policies where FFP and PLT are given in 1:1 ratios to RBC seem to counteract 
coagulopathy according to trauma literature.175,176 Further research is needed to investigate 
how different strategies of transfusion affect coagulopathy and how this applies to repair of 
AAA.  
1.7.1.3 Measuring hemostasis in AAA repair 
The commonly used tests to measure aspects of hemostasis are imprecise in validating the 
functionality of the hemostatic system.177 The point-of-care tests using viscoelastic methods 
to measure thrombus formation (eg. TEG and ROTEM) are gaining popularity and might 
after further evaluations become gold standard.151,177  
Activated clotting time (ACT) is a bedside test that primarily measures the effect of heparin. 
However it offers a test complement to use also in evaluating coagulopathy.177 ACT is 
commonly used as verification of the given heparin in cardiac, vascular and endovascular 
surgery.168 In EVAR the goal ACT is 200-250 s to ensure a low risk of thrombotic 
complications. Boluses of heparin are given intravenously to maintain an adequate ACT. 
To assess the functionality of platelets a variety of specific tests are available. TEG/ROTEM 
have previously been criticized for being insensitive for platelet dysfunction.177 The most 
common specific platelet function tests are presented in Table 1.  
Most of the tests described in Table 1 offer specific measurements of individual parts of the 
hemostasis and will probably remain important in pinpointing specific deficits and weak 
spots in the hemostatic process. 
The different methods of repair and also the acuteness of the AAA repair put different 
requisites to the measurements of hemostasis. To early detect a hypercoagulable state is just 
as important as identifying coagulopathy.  
The perfect, quick, reliable, accurate, easy to use and cheap bedside test for assessing all parts 
of the hemostasis adapted to the demands of AAA repair is not yet identified. 
1.7.1.4 Anti-coagulation medicines in AAA repair 
According to a large retrospective material including 5527 patients undergoing elective AAA 
repair, 8% of the patients were on anticoagulation medicine or had bleeding disorders 
preoperatively.178 It is common practice that patients on warfarin are advised to discontinue 
or alter their medication to LMWH before elective AAA repair. 
In elective vascular surgery thrombotic prophylaxis is routinely given pre- and 
postoperatively in the form of LMWH. Different regimes exist but commonly LMWH is 
given subcutaneously 4-8 h postoperatively for one week or more in order to reduce the risk 
of postoperative deep venous thrombosis. Also during surgery anticoagulatory measures are 
taken by intravenous (IV) administering Heparin as a bolus dose of 5000 U (or individualized 
to patient approx. 70-100 IU/kg) before clamping the aorta or introducing large diameter 
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sheaths into the vessels during EVAR to reduce the risk of perioperative thrombosis. A 
survey from 1994 explored the use of Heparin among vascular surgeons in the USA and 
Europe.179 An aggressive use of Heparin and reversal with Protamine was described. A recent 
survey study in UK reports that 95% of surgeons use IV Heparin in open AAA repair and 
85% in AAA repair by EVAR.180 ACT measures the effect as described above. During rAAA 
the same measures are usually not performed as coagulation deficiency is expected due to the 
bleeding. According to a recent review there is however no scientific evidence that supports 
not giving heparin also in rAAA for both OR and EVAR.168  
Some patients presenting with rAAA might be on continuous anticoagulation medication. 
The most common is warfarin but new oral medications (NOACs- new oral anticoagulants) 
are gaining popularity. Some of the new anticoagulants (e.g. the FX inhibitors) are lacking 
antidotes, which could cause serious bleeding problems in an emergency surgery situation. 
Warfarin can be reversed by vitamin K, plasma or more rapidly by prothrombin complex 
concentrate (PCC). The effect of heparin and LMWH can be reversed by protamine.155  
1.7.1.5 Platelet inhibition in abdominal aortic aneurysm repair  
In elective AAA repair patients on antiplatelet medication are usually kept on their medicine 
as secondary prophylaxis in order to reduce the risk of myocardial infarction and stroke. The 
prevalence of AAA patients on ASA differs in literature 13-49%.65,67 A prevalence of >50% 
cardiac comorbidity is frequently reported.181 In the ADAM screening study for AAA a 
comorbidity of atherosclerosis was reported in 36%.67 No randomized trials investigate the 
benefit of platelet inhibition in AAA patients. A meta-analysis from 2002 suggests that 
patients with known arterial occlusive disease have a yearly 25% risk reduction for 
cardiovascular event if on long-term antiplatelet medication.182 ASA is the most commonly 
used antiplatelet medicine followed by Clopidogrel. Modern antiplatelet drugs such as 
Ticagrelol are becoming more common and we might expect that they will be more 
frequently used also in patients with known or unknown AAA. In perioperative hemostasis 
this can become a problem if emergent surgery is needed considering the long half-life and 
the profound effect that the modern drugs imposes on platelet function.  
Patients presenting with rAAA might be on platelet inhibitory drugs. No antidotes are 
available to these drugs. The only way to increase the platelet functionality is to transfuse 
platelets. In patients on Ticagrelol several platelet transfusions can be required, as active 
medicine still is present in the blood.  
1.7.2 Bleeding in AAA repair 
1.7.2.1 Method of repair 
1.7.2.1.1 Elective AAA 
Open AAA repair has always been considered to be associated with a high risk of large 
volume bleeding. Thorough preparation and meticulous operative technique can reduce the 
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perioperative blood loss but, but as it seems in comparative literature OR vs. EVAR, only to a 
certain extent in low risk elective patients.178 
According to two randomized controlled trials (RCT) comparing elective OR and EVAR the 
perioperative bleeding in OR ranges between 1000-1500 ml compared to EVAR with 
substantially lower perioperative bleeding volumes of 200-400 ml.111,112,183  
1.7.2.1.2 Ruptured AAA 
Also in ruptured AAA patients, different bleeding volumes are reported according to method 
of repair. In EVAR patients the mean blood loss for rAAA range from 200 ml to 1100 ml and 
in OR patients it ranges from 2000-4500 ml according to a review from 2007.184 Out of the 
three randomized controlled trials (Nottingham, AJAX and IMPROVE trials) comparing OR 
and EVAR for rAAA the two first reported significant difference in perioperative blood 
transfusion.132-134 The IMPROVE trial did not report blood loss or transfusion. Other rAAA 
studies have showed decreased bleeding volumes and transfusion requirements for 
EVAR.132,185,186 Transfusion volumes in EVAR vs. OR for rAAA patients were reported to 
range between mean (units) of 0-3.78 and 6-10.7 respectively in a review.184 
1.7.2.2 Perioperative bleeding 
Bleeding is a feared complication to elective AAA surgery. Large volume bleeding in open 
AAA repair can occur during the procedure due to iatrogenic injuries to arteries and veins 
during dissection and the rest of the course of the surgery. Brisk back bleeding from lumbar 
arteries or the inferior mesenteric artery after opening the aneurysm sac can also be 
encountered. Bleeding can also occur when failing to obtain adequate proximal and distal 
control over the aorta and iliac or femoral arteries. The trauma of the surgical procedure and 
the added bleedings during the surgery can also induce coagulopathy.  
In EVAR for elective AAA the most frequent cause of perioperative bleeding is the failure to 
ensure adequate sealing and closure of the femoral access sites during and directly after the 
procedure. Introducers of varying diameter sizes are used to deliver the endovascular grafts 
necessary for repair. In the changing of introducers bleeding can occur. The access sites must 
be securely closed after completing the aortic repair. This can be achieved using different 
methods such as open raphie of the artery, closure devices and as studied in Paper I, the fascia 
suture technique. The failure to adequately close the femoral access sites can lead to 
significant perioperative and postoperative bleedings. 
In rAAA significant bleeding many times starts and continues from the time of the rupture. 
The aorta is located in the retroperitoneal space, in many cases the bleeding after the initial 
AAA rupture and is contained to a limited space in the retroperitoneum. See Figure 9. A free 
intraabdominal aortic wall rupture would inevitably lead to the rapid emptying of the 
patients’ blood volume. The containment of the bleeding after rupture leaves a treatment 
window of opportunity before the containment finally bursts into the abdominal cavity. The 
Introduction 
 35 
length of the treatment window is not well known and varies due to the physiologic 
uniqueness of each patient.65,128  
 
Figure 9. Computer tomography angiogram of a ruptured abdominal aortic aneurysm with a large 
retroperitoneal hematoma 
1.7.2.3 Postoperative bleeding  
Postoperative bleeding is defined as bleeding that takes place in the postoperative period. 
After open repair postoperative bleeding can be caused by anastomotic leakage, iatrogenic 
injuries and coagulopathy induced during and/or after the surgery. Postoperative bleeding 
after EVAR usually occur from the femoral access sites but can also be caused by 
endoleakage, iatrogenic injury to the aorta, the iliac arteries and other vessels. 
After repair of rAAA, postoperative coagulopathy is a known risk for postoperative 
bleedings. Postoperative bleeding is suggested as one explanation to abdominal compartment 
syndrome in both OR and EVAR after rAAA.187,188 
1.7.3 Blood transfusion in AAA repair  
1.7.3.1 Transfusion in AAA patients 
Scientific evidence from studies of massive bleeding in trauma and other fields suggests 
replacing blood loss by transfusing patients with blood products that resembles the 
constitution of whole blood as much as possible.175,189 The RBC:FFP ratio has been shown to 
impact survival in trauma patients with massive hemorrhage.175 The latest guidelines describe 
evidence supporting using ratios of 1:1:1 RBC:FFP:PLT and early administration of 
coagulation factors.190 It is a general practice that these should be applied to all patients 
requiring MT.157 In AAA repair it has not been proven that a strict coherence to transfusions 
guidelines is beneficial for the outcome of these patients. 
The optimal hemostatic resuscitation of patients with rAAA undergoing OR or EVAR has not 
been well defined. EVAR in rAAA has been described to be associated with decreased 
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bleeding volumes and transfusion requirements. 132,185,186 In aortic surgery only a few studies 
have tried to investigate transfusion regimes.191,192 No randomized control study exists. As 
ruptured open repair AAA patients often require MT, this group offers a potential study 
population to further develop the optimal transfusion strategy for this patient category.  
According to a report from Mann et al 2011, the routine of cross-matching blood preoperative 
to elective EVAR is unnecessary. In a series of 203 consecutive EVAR cases only 3 patients 
required massive transfusion. Only 6 % of the patients required any transfusion.193  
1.7.3.2 Transfusion recommendations in ruptured AAA patients of today 
It might be suggested that the massive hemorrhage observed in rAAA patients calls for 
coherence to the existing massive transfusion guidelines also in these patients. Only a few 
previous studies have evaluated blood transfusion in patients undergoing rAAA repair. In 
2010 Mell et al. reported reduced mortality in patients receiving an equivalent ratio of FFP 
and RBC and also concluded an advantage to early plasma transfusion in rAAA patients.192 
In 2007 Johansson et al. reported that proactive administration of platelets and FFP has 
positive effects on coagulation and survival.194 
The optimal transfusion strategy in rAAA has not been completely investigated.  
1.7.4 Summary 
The repair of AAA benefits from a thorough understanding of problems related to 
hemostasis, coagulopathy, bleeding, and blood transfusion. A structured workup with regard 
to increased risk for bleeding with patient history, medications, and preoperative coagulation 
tests should be the standard procedure before AAA repair regardless the method.82  
Preparedness in the surgical team and close collaboration with the blood bank and 
coagulation laboratory is important in order to provide quick and adequate response in case of 
major bleeding in rAAA repair. Endovascular repair has decreased the need of transfusion in 
elective end emergency repair of AAA.  
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2 AIMS OF THE THESIS 
 
The overall aim of this thesis was to investigate the clinical problem of bleeding in open and 
endovascular repair in both ruptured and elective abdominal aortic aneurysms. Aspects on 
bleeding and association to risk factors and outcome in this patient group were studied. 
 
In the four studies the following specific aims were addressed: 
• To investigate if the fascia suture technique for femoral access site closure after 
EVAR is a safe method for obtaining perioperative hemostasis and vascular closure 
and if risk factors for failure of the method could be identified. 
• To evaluate the outcome and predisposing factors related to perioperative bleeding in 
patients treated with endovascular aneurysm repair for ruptured and non-ruptured 
abdominal aortic aneurysms. 
• To investigate coagulation laboratory tests and their association to preoperative 
hemodynamic status, perioperative bleeding and outcome in patients undergoing 
repair for ruptured abdominal aortic aneurysms. 
• To study the effect of blood transfusion and blood product ratios on outcome in 
massively transfused patients treated for ruptured abdominal aortic aneurysms. 
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3 PATIENTS AND METHODS 
3.1 STUDY DESIGN PAPERS I-IV  
In these studies the subjects were primarily identified through local or national vascular 
registries and matched with the local computerized medical records and databases by their 
Swedish personal identification number.  
The Swedish Vascular Registry (Swedvasc) was used in Studies II-IV. The Swedvasc is 
continuously matched to the national mortality registry thereby providing automated update 
of mortality. 
The local laboratory database at Karolinska University Hospital was used in Study II and III.   
The regional transfusion registries of Skåne University Hospital and the Stockholm Region 
were used in Study IV. 
Table 2 shows a summary of the patients, methods, study designs and centers used in the 
Studies I-IV.  
Table 2 Overview of study designs, patients, methods and centers involved 
 Patients and materials Study design and methods Centers 
Study I 100 consecutive patients 
undergoing elective or emergent 
EVAR 2007-2008  
Retrospective follow-up study of 
fascia suture technique, results and 
preoperative risk factors for failure 
Dept. of Vascular 
Surg. Skåne 
University Hospital   
Study II 525 consecutive patients treated 
with elective or emergent EVAR 
2008-2011 
Retrospective study of perioperative 
bleeding and the effect on outcome  
Dept. Vascular 
Surg. Karolinska 
and Skåne 
University Hospital   
Study III 91 consecutive patients treated for 
ruptured AAA by open repair or 
EVAR 2008-2013 
Study of preoperative coagulation 
tests and the relationship to bleeding 
and outcome 
Dept. Vascular 
Surg. Karolinska  
Study IV 369 rAAA patients undergoing 
open repair or EVAR 2008-2013 
Retrospective analysis of transfusion 
ratios and timing in massively 
transfused patients 
Dept. Vascular 
Surg. Karolinska, 
Skåne University 
Hospital and 
Södersjukhuset 
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3.2 ETHICAL CONSIDERATIONS 
3.2.1 Ethical considerations Paper I 
Paper I was a quality assurance study of a newly introduced surgical method (FST) for 
closing the femoral access site after EVAR. According to the Malmö University Hospital 
practice in similar cases no application to the local ethics committee was needed in order to 
conduct this follow-up study. The patients studied were unaware of this newly implemented 
method of closure that was, earlier, reported as safe and associated with few complications.195 
The alternatives to FST before introduction of the method, was surgical cut down and lateral 
arterioraphy or suture mediated closure devices (double ProStarXL®). Surgical cut down is 
known to be a safe method, however associated with a considerable risk of complications 
such as perioperative and postoperative bleeding, infection and lymphatic leakage. According 
to a systematic review of 13 EVAR studies performed with surgical cut down the local 
wound complication rate varied from 2-26%.196  
The use of suture mediated closure devices such as the double ProStarXL® was at this time 
used outside the instructions for use provided by the company. The method has been 
previously studied and shown to be safe and associated with acceptable risks of 
complications.108 The double ProStarXL® method however also have, disadvantages such as 
cost and prolongation of the surgical procedure, which poses possible problems especially in 
rAAA patients where a speedy procedure is of vital importance. A failure rate of 2%-10 % 
has been described.107  
There was an apparent need of an alternative method for simplifying closure of the femoral 
access sites after EVAR at the time of the implementation of the FST. The study did not 
imply deviation from the normal practice of follow-up or other aspects of treatment not 
related to the closure of the femoral access sites, for the patients.  
3.2.2 Ethical considerations Paper II-IV 
The regional ethics committee in Stockholm approved studies II-IV (reference number 
2011/664-31/3). The retrospective nature of these studies meant no deviation from normal 
treatment or follow-up. All data was collected from registries, data banks and computerized 
medical records all of which previously has been under thorough investigation concerning the 
ethical aspects of data management and usage. The studies were performed according to 
Declaration of Helsinki and the Karolinska Institutets guidelines for good ethical practice.197 
The data banks were anonymized and kept secured from unauthorized use. 
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3.3 PATIENTS AND METHODS PAPER I 
In this study the aim was to evaluate the efficacy, safety and preoperative risk factors for 
failure of the fascia suture technique (FST), previously described by Dietrich 1997.198 It was 
a retrospective study of 100 consecutive EVAR patients at a tertiary high volume vascular 
surgery center. 
3.3.1 Inclusion 
The new method of FST for closing of the femoral access sites after EVAR was introduced at 
Malmö Vascular Center in 2007. It was decided that the technique should be used as the first 
hand method by all surgeons performing EVAR. Data was collected prospectively and 
analyzed retrospectively in order to evaluate the method with regard to success, safety and 
outcome. Clinical examination and CTA was included at 30-day and 1-year follow-ups 
within the analysis. It was decided to consider 100 consecutive EVAR patients for inclusion 
in the study. Patients were enrolled during the study period of 1 March 2007 until 21 April 
2008. See Figure 10. 
 
 
 
 
 
 
 
 
 
Figure 10. The flow chart illustrates the study material 
 
In the 100 consecutive patients a total of 187 femoral access sites were used. In 160 of these 
FST was the primary method of closure. These access sites comprised the study material. A 
number of 27 access sites were excluded as they were primarily chosen for open access and 
closure by raphie or patch closure. One case was closed with closure device.  
100 Consecutive EVAR patients: 
• 70 infrarenal bifurcated Stent grafts (SG) 
• 15 fenestrated SGs 
• 13 infrarenal aorto-uni.iliac SGs 
• 2 combined abdominal & thoracic SGs 
187 Femoral Accesses 
27 Accesses excluded: 
• 13 fem-fem crossover bypasses 
• 13 cut down + patch repairs 
• 1 closure device 
160 FST femoral access sites for 
analysis 
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3.3.2 Pre- and postoperative imaging 
The patients preoperatively underwent a CTA of the aorta and femoral access sites for 
planning of the EVAR procedure. The pre- and postoperative follow-up CTAs (1-month and 
1-year) performed at other centers were sent to Malmö Vascular Center for evaluation.  
3.3.3 Risk factor and grade of stenosis assessment by computer 
tomography 
3.3.3.1 The puncture site 
As the exact location of the puncture site was unavailable both before and after the EVAR, 
the puncture site on CTA was assumed to be located on the mid part of the common femoral 
artery between the epigastric artery and the femoral bifurcation. All measurements were 
calculated as mean values of three individual measurements, at 5 mm intervals, at the 
assumed site of the arterial puncture. 
Figure 11 describes the measurements and evaluation of the CTA with regard to studied risk 
factors and grade of stenosis.  
 
Figure 11. Stenosis calculation (x-diameter contrast lumen/y-diameter inner lumen) × 100 
3.3.3.2 Subcutaneous fat layer above in the groin 
The subcutaneous fat layer was evaluated as a possible risk factor for failure of the technique 
as it previously had been described that obesity could be a contraindication to percutaneous 
EVAR approach.4 Instead of using body mass index (BMI) we used the subcutaneous fat 
layer lying above the stipulated puncture site as we thought this was a more logical measure 
to consider as it directly describes the presence of excessive fat in the area of interest instead 
of the whole body. The fat layer was measured in the anterior-posterior projection from the 
arterial wall to the skin (Figure 11).  
3.3.3.3 Calcification of the femoral artery and grade of stenosis 
Excessive atherosclerosis in the access vessels has previously been described as a risk factor 
for percutaneous EVAR with a possibly higher failure rate of percutaneous femoral 
closure.4,199 In order to evaluate this the plaque burden of the common femoral artery was 
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assessed at the assumed puncture site. After evaluating a number of access sites a grading 
system for describing the femoral calcification was agreed upon (Figure 12), which was used 
throughout the study. Table 3 presents the definition of calcification grades used. 
 
Figure 12. Grading system for assessing the calcification burden 
Table 3 Definition of calcification grades 
Plaque CTA Definition 
Grade I No visible plaque 
Grade II <25 % 
Grade III >25 % 
Grade IV >50 % 
Grade V Anterior plaque 
 
To evaluate the grade of stenosis the ratio was calculated between diameters of the mean 
inner contrasted lumen (x) and the mean outer vessel wall (y) of the common femoral artery 
at the assumed puncture site. A percentage-estimated stenosis was obtained through (x/y × 
100). See Figure 11. At 1-year follow-up, comparing the preoperative with the postoperative 
assessed the change in grade of stenosis. 
3.3.4 Closure of femoral access sites, the Fascia Suture Technique 
In this study the fascia suture technique was evaluated. It was previously described by 
Dietrich 1997 and Larzon 2006.195,198  
Operative technique FST: 
After completion of the EVAR procedure the introducer with its inner sheath is reinserted 
into the femoral artery and an approximately 4 cm long transverse skin incision is made. The 
subcutaneous layer is then bluntly dissected to the cribriform fascia overlaying the femoral 
sheath and lymphatic tissue of the groin. An inversed U-stitch in the cribriform fascia is 
placed using a non-absorbable monofilament 2-0 or larger suture. The stich should include 
the access passage of the reinserted introducer and the area directly above the puncture site. 
After tightening the first throw of a conventional knot the introducer is withdrawn leaving the 
guide wire in place when accessing the hemostasis. If the hemostasis is considered sufficient 
the guide wire is withdrawn and the knot is further tightened and completed. If the first fascia 
Carl Montán 
44 
suture fails a second can be placed. If hemostasis is inadequate after a second fascia suture, a 
cut down should be performed. 
The influence of introducer size (Fr) to the failure rate of the method was evaluated. The 
impact of FemoStop® use on outcome of FST was also studied. 
3.3.5 Outcome measures 
To evaluate the method, outcome measures were; primary success defined as adequate 
hemostasis and complications at 1-month and 1-year follow-up. Immediate failures were 
considered as: 
• insufficient hemostasis resulting in a formal cut down and exposure of the artery and 
lateral arterioraphy with or without patch 
• limb ischemia observed directly postoperatively, also resulting in formal cut down 
with arterial repair.  
• other techniqual failures possibly resulting from the FST 
At 1-month and 1-year follow-up the following were evaluated: 
• any adverse event that could be linked to the FST including late postoperative 
bleeding, groin infection etc. 
• presence of pseudoaneurysm at 1-month and 1-year CTA follow-up 
• grade of stenosis observed at 1-year postoperative CTA related to preoperative 
measure at CTA (on 1-month follow-up CTA grade of stenosis was not calculated) 
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3.4 PATIENTS AND METHODS PAPER II 
In Study II the aim was to analyze perioperative bleeding related to outcome in patients 
treated with EVAR for non-ruptured AAA and rAAA. The study population comprised 525 
EVAR patients from two vascular centers. Data concerning the operative procedure i.e. stent 
graft devices, introducer sizes, and methods of closure of access sites were analyzed in order 
to find risk factors for increased perioperative blood loss.  
3.4.1 Inclusion and data collection 
This was a retrospective study of all patients treated with EVAR for non-ruptured and 
ruptured AAA at Malmö Vascular Center and the Department of Vascular Surgery at 
Karolinska University Hospital between 1st of April 2008 until 31th of August 2011.  
Patients and comorbidities were identified from Swedvasc and entered into a database. Data 
was also retrieved from the local medical records and operative charts and added to the 
database concerning preoperative, operative and postoperative variables. Blood chemistry 
data was collected from the local laboratory databanks. Time of procedure was collected from 
the local computerized operative planning tool. The blood loss was retrieved from the 
Swedvasc and the anesthetists’ operative charts. 
The study cohort included 435 non-ruptured (elective n=382, symptomatic n=53) and 90 
rAAA patients. 
3.4.2 Data analysis and outcome measures 
Subgroup analysis was performed as appropriate for the rAAA and non-rAAA (elective or 
symptomatic) groups in order to avoid case bias. The three groups constituted different 
categories of patients with regard to pathophysiology, hemodynamic status and difficulty in 
repair. Outcome measures were not deemed as comparable between the groups. 
3.4.2.1 Perioperative blood loss 
Perioperative bleeding was categorized into four groups according to Swedvasc based upon 
the estimated volume of blood loss: <1000 ml, 1000-1999 ml, 2000-5000 ml, and >5000 ml. 
The blood volume was crosschecked with the estimated blood loss in the anesthetists’ 
operative chart.  The perioperative blood loss was then correlated to preoperative and 
perioperative variables.  
3.4.2.2 Femoral access site closure 
The primary methods of closure for the femoral access sites were analyzed with regard to 
technical success and were related to perioperative blood loss.  
3.4.2.3 Outcome measures  
Thirty-day mortality was the primary outcome measure. Morbidity outcome measures studies 
were renal failure, multi organ failure (MOF), bowel ischemia, abdominal compartment 
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syndrome (ACS) and >5-days ICU stay. The outcome measures were analyzed in uni- and 
multivariable logistic regression models in relation to perioperative blood loss and other 
perioperative variables. 
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3.5 PATIENTS AND METHODS PAPER III 
In Study III the aim was to analyze a number of preoperative coagulation parameters (known 
to be relevant to assess coagulopathy) and their association with preoperative hemodynamic 
status, perioperative bleeding, and outcome in patients presenting with rAAA. A retrospective 
single center study of rAAA patients undergoing either open (OR) or endovascular (EVAR) 
repair was conducted. 
3.5.1 Inclusion and data collection 
The Study cohort included 91 rAAA patients that presented to Karolinska University Hospital 
between 1st of May 2008 until 31st of August 2013. During the study period 121 patients with 
rAAA presented to our clinic. Thirty patients were excluded from the study due to missing 
data. The 30 excluded patients did not differ from the study cohort regarding demographics or 
outcome. The included patients were treated by open repair (OR) (n=72, 79%) or EVAR 
(n=19, 11%).  
3.5.2 Laboratory data 
Laboratory data were collected at the patients’ arrival to the emergency department. Quality 
assured methods for analyzing blood samples were used. The blood samples analyzed are 
presented in Table 4. 
Table 4. Reference ranges of laboratory values used in Paper III 
Blood test Reference range 
Fibrinogen     [2.0-4.0 g/L; 200-400 mg/dL] 
Hemoglobin   [female/male 117-153/134-170 g/L] 
Platelet count [165-387/145-348 109/L] 
Prothrombin time ratio (PTr-INR) [<1.2] 
Activated partial prothrombin time (APTT) [28-40 s] 
S-Creatinine  [<90/<100 µmol/L] 
3.5.3 Measuring perioperative bleeding 
The blood loss was retrieved from Swedvasc and the anesthetists’ operative charts. 
Perioperative bleeding was categorized into three groups according to Swedvasc based upon 
the estimated volume of blood loss: 0-1999 ml, 2000-5000 ml, and >5000 ml. The original 
categorization of four separate groups were adjusted into three groups by adding the <1000 
ml and 1000-1999 ml groups together. There were two logical reasons for this. Firstly, in 
Paper II perioperative bleeding >2000 ml demonstrated a significant difference on outcome. 
Secondly, to avoid small groups making statistical analysis difficult.  
The perioperative blood loss was correlated to pre- and perioperative variables.  
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3.6 PATIENTS AND METHODS PAPER IV 
In this study the aim was to investigate the effect of blood transfusion and blood product 
ratios on outcome in massively transfused rAAA patients undergoing open repair or EVAR. 
The effects of early administration of FFP and PLT on outcome were analyzed as well as 
different transfusion strategies during the study period. 
Patients were analyzed in total and separately as appropriate according to operative methods.  
Only patients that were massively transfused (MT) were analyzed with regard to transfusion 
ratios and time and association to outcome. 
3.6.1 Inclusion and data collection 
The study was performed at three of the largest vascular centers in Sweden; Karolinska 
University Hospital, Södersjukhuset (Stockholm) and Skåne University Hospital (Malmö). 
All rAAA patients in Swedvasc undergoing repair by EVAR or open surgery during the study 
period (May 8, 2008 to December 31, 2013) were considered for inclusion. The final study 
cohort consisted of 369 patients.  
Massive transfusion (MT) was defined as ≥4 units RBC transfused in 1 h or 10 units of RBC 
transfused in 24 h.157 Patients reaching either of the two definitions were declared as patients 
requiring MT. 
Patients that died before aortic repair was attempted as well as patients that died in the 
operating theatre were excluded from analysis of transfusion ratios and timing as the 
transfusion strategy was considered not to determine their outcome. 
Patient data, medical history and data related to the rAAA repair and outcome were collected 
from Swedvasc and the hospitals medical records. Blood transfusion data was captured from 
the local transfusion registries. The transfusion registries included data on exact issuing time, 
number of units and type of blood products ordered.  
3.6.2 Method of repair 
EVAR was the preferred primary method of repair in rAAA at the enrolled centers. However 
the vascular surgeon in charge decided upon the method of repair according his or her 
judgment. The complexity of anatomy, hemodynamic status, personal competence in 
performing advanced EVAR or complex open repair, and the hospitals resources were all 
factors that were processed before deciding upon the method of repair. 
3.6.3 Transfusion data and blood products 
Red blood cells (RBC) were administered in units of 280 ml. The plasma units of 
approximately 250 ml were prepared as either fresh frozen plasma (FFP), stored in -30oC or 
fresh plasma stored up to 14 days at +2-+6oC. Platelets were prepared by centrifugation from 
four to six donors and kept at +22oC under continuous gentle agitation. Each unit contained 
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>240 x109 platelets suspended in 350 ml, 70% platelet additive solution (PAS) and 30% 
plasma. All blood components were prestorage leukocyte reduced.  
The recommended ratio of FFP:RBC transfusion in massively transfused patients in Sweden 
is, according to national guidelines, 1:1.159 The recommended ratio of PLT:RBC is defined to 
1:4 and not 1:1, as in Sweden a transfusion unit of PLT are pooled from 4-6 donors. 
3.6.4 Outcome measures 
The primary outcome measure was 30-day mortality.  
The variable “Any complication” in Swedvasc was chosen for morbidity. The methodology 
used when measuring associations is presented in the statistical considerations section for 
Paper IV. 
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3.7 STATISTICS 
3.7.1 General statistical considerations Papers I-IV 
Descriptive statistics, including means, medians, standard deviations, ranges, interquartile 
ranges (IQRs) and proportions, were calculated as appropriate. 
Chi-square, Mann-Whitney U tests, Kruskal-Wallis Test, Students T test or Fisher’s exact 
tests were used, to compare nominal variables between data as appropriate. Chi-square tests 
were performed for contingency tables. The Wilcoxon signed rank test was used for paired 
data. Significant relationships in univariable and multivariable logistic regression models 
were expressed as odds ratio (OR) with 95% confidence interval (CI). P-values of <0.05 were 
considered as statistically significant. 
3.7.2 Statistics Paper I 
As distribution of data was skewed, nonparametric tests were performed. In addition to the 
analysis of the suggested predictors of FST failure (i.e. preoperative CFA stenosis, plaque 
grade, and obesity), the size of the introducer sheath was evaluated. The introducer sheath 
diameters, range (14 to 24 F), were dichotomized as large (18–24 F) and small (14–16 F). 
Any influence of the FemoStop® on outcomes was also evaluated. 
3.7.3 Statistics Paper II-III 
Univariable analysis of binary, nominal and ordinate variables was performed. Variables 
associated with increased blood loss (P<0.05 in univariable analysis) were analyzed in a 
logistical regression model.  
3.7.4 Statistics Paper IV 
The associations between both a) time to first transfusion and thirty-day mortality and b) 24-
hour ratio and thirty-day mortality were modeled using logistic regression. Associations for 
FFP and PLT were analyzed separately. Time to first transfusion was modeled as an 
interaction between a dummy variable indicating whether transfusion was received or not and 
a continuous variable measured in log (hours from first order of blood products+1). A main 
term for the dummy variable, but not the continuous variable, was included in the model. 
Both crude and adjusted analyses were performed. Time to first transfusion was adjusted for 
age. 24-hour ratio was adjusted for age and total amount of transfusion. The analyses were 
stratified according to operation type (endovascular or open repair).  
As variable for morbidity the Swedvasc variable of “Any 30-day complication” was analyzed 
against transfusion volumes, timing and ratios. Cubic splines with three knots were used to 
relax the assumption of linearity between exposure and outcome whenever feasible. 
To test if the 24-hour ratio of FFP to RBC and PLT to RBC changed during the study period, 
we compared the ratio for the years 2008 to 2010 with the ratio for the years 2011 to 2013 
using a median test. 
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4 RESULTS AND DISCUSSION 
In the following section the results for each of the papers are presented, followed by 
comments and discussions of the findings.  
4.1 RESULTS AND DISCUSSION PAPER I 
In Paper I the immediate success and failure rate of the fascia suture technique for closing the 
femoral access site after EVAR was analyzed. A total of 160 femoral access sites out of 100 
consecutive EVAR patients were studied.  
4.1.1 Short and mid-term results 
The technical success was 146/160 (91%). The 14 failures were converted to open exposure 
of the femoral artery and raphie intraoperatively or in direct conjunction to the primary 
surgery. Eleven were due to inadequate hemostasis and 2 due to limb ischemia following the 
femoral access site closure. One patient had to be opened because of a broken guide wire tip 
that had to be retrieved.  
At 30-day follow-up 2 complications were detected. The first complication was a late 
postoperative bleeding 2 weeks after the procedure that presented to the emergency ward. 
The second was an infected pseudoaneurysm that also presented after 2 weeks. Both cases 
had to undergo emergency surgery and the infected pseudoaneurysm was also treated with 
intravenous antibiotics. No other complications were noted at 1-month follow-up.  
At the 1-year follow-up nine <1 cm pseudoaneurysms were suspected on CTA. None of these 
required extra follow-up or treatment. Data presented in Table 5. 
Table 5. Outcome Fascia Suture Technique 
Immediate outcome & follow-up of femoral closures by Fascia Suture Technique 
 
Immediate Outcome (n=160) 1-month (n=146) 1-year (n=146) 
146 (91%) technically successful 144 successful 137 successful 
14 failures: 
11 bleeding 
2 limb ischemia 
1 broken guide wire 
2 complications: 
1 bleeding 
1 infected PA 
9 complications: 
9 <1 cm PA 
(Conservative treatment) 
PA = pseudoaneurysm 
4.1.2 Risk factors for failure of Fascia Suture Technique 
The possible influence of the diameter of the introducer sheaths to the outcome of the FST 
was evaluated. There was no correlation between failure and introducer size (p=0.803). The 
use of FemoStop® (used in 55% of cases) had no influence on the FST outcome (p=0.866). 
Carl Montán 
52 
No preoperative risk factors predicting failure of FST were found. Patients with a deeper 
subcutaneous fat layer were not significantly more prone to a higher failure rate of FST 
(p=0.08). The calcification at the femoral access sites did not influence outcome of the FST 
(p=0.12). Distribution and outcome between Grade I-V presented in Table 6.  
Table 6 Distribution of calcification grades in cohort and immediate failures 
Calcification as a Possible Risk Factor for FST failure (n=145) 
 Primary hemostasis Failure 
Grade I (n=50) 47 3 
Grade II (n=32) 31 1 
Grade III (n=26) 22 4 
Grade IV (n=11) 11 0 
Grade V (n=27) 22 5 
Total (n=145) 132 13 
 
The grade of stenosis was not significantly related to worse outcome of the technique 
(p=0.23). 
4.1.3 Discussion Paper I 
4.1.3.1 General comments 
Study I evaluated the short and mid-term results of the FST for closure of femoral access sites 
after EVAR.  
The technique seems to be safe and effective, and simple to use. Preoperative obesity, 
femoral calcification, stenosis or large diameter introducer sheaths did not affect the outcome 
in this study.  
4.1.3.2 Short and mid-term results 
The 91% success rate of the FST in this study was similar to that described in other 
studies.105,195,200 Compared to other methods of closing the femoral access sites after EVAR it 
offers similar safety and complication rates. Numerous trials evaluate the preclose method 
(double ProStarXL®) for closure of femoral access sites.108,201,202 According to a meta-
analysis 2013 the overall success rate for the preclose technique was 94% per femoral 
access.108  
4.1.3.3 Pseudoaneurysms 
The clinical significance of the pseudoaneurysms noted at 1-year follow-up is unknown. It is 
difficult to compare the frequency of pseudoaneurysms observed in this study to that of other 
closure methods as many studies have used duplex ultrasound or simply clinical examination 
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at follow-up. Other studies have also reported postoperative pseudoaneurysms after FST 
ranging from 3% - 13.9%.105,195,200 The reported intervention rate at 1 year was however 
<1%. It should be noted that the presence of these small pseudoaneurysms could pose a 
potential danger for late complications if they should grow in size. No late follow-up reports 
have yet been published. 
A valid skepticism still exists towards the FST and few centers use this method as the first 
choice for closing the femoral access sites. However there are indications that the method is 
gaining poplularity.203  
4.1.3.4 Possible risk factors for FST failure 
The study includes 14 early failures and two 1-month complications, representing a 9% 
failure/early complication rate. Statistical analysis for preoperative risk factors is bound to be 
questionable due to the small number. A larger material would better help us investigate risk 
factors and avoid a type B statistical error. As described by others, the FST seems to function 
well also in patients with deep groins or in patients with calcified arteries.204  
A subjective caution to avoid heavy calcification on the anterior wall has been described.203 
In this study anterior plaque in the area of the puncture site was not deemed as significantly 
associated with failure. When calculating significance of difference in failure rates between 
the Grade V plaques against the other plaque grades I-IV a p-value of 0.06 is found in a 
contingency test using Chi2. It could be argued that the failure to reach a significant p-value is 
due to a type B error. A cautious approach towards using FST for deep femoral groins and 
femoral arteries with anterior plaque could be suggested.  
The number of femoral access sites in this study did not demonstrate an increased risk of 
postoperative stenosis.  
4.1.3.5 Limitations 
The main limitations are the cohort size number and the retrospective nature. A prospective 
randomized trial comparing FST with other methods of closure would be preferable. In this 
study no comparable method of closure was studied and the comparison to other methods can 
only be done by comparing results from other studies that may differ in case selection.  
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4.2 RESULTS AND DISCUSSION PAPER II 
This study analyzed perioperative bleeding related to outcome in patients treated with EVAR 
for non-ruptured and ruptured AAA.  
4.2.1 Study cohort 
The study included 525 EVAR patients (435 non-ruptured AAA and 90 rAAA) from two 
vascular centers. The including data concerning demographics, comorbidities and medical 
therapies are presented in Table 7. 
Table 7 Demographics, comorbidities and medical therapy 
Factor Non-ruptured AAA 
(n=435) 
Ruptured AAA               
(n=90) 
Age 73 (50-89) 74 (58-89) 
Male sex 370/435 (85 %) 73/90 (81%) 
Comorbidities   
Diabetes 31/286 (11 %) 13/60 (22 %) 
Hypertension 210/283 (74 %) 41/55 (74 %) 
Heart risk 105/278 (38 %) 24/55 (44 %) 
Blood Chemistry   
Hb 135 (69-173) 131 (75-169) 
s-Creatinine 93 (42-956) 109 (35-373) 
PTr-INR 1.0 (0.8-4.6) 1.0 (0.9-3.1) 
Medical therapy   
Acetylsalicylic acid 301/432 (69 %) 46/88 (51%) 
Clopidogrel 15/431 (3.4 %) None reported 
Warfarin 42/432 (9.6 %) 5/88 (5.6%) 
AAA- Abdominal Aortic Aneurysm; PTr-INR- Prothrombin time ratio-International 
Normalized Ratio 
Data concerning the operative procedure and devices and methods of closure of access sites 
were analyzed in order to find risk factors associated with increased perioperative blood loss.  
Out of the 435 non-ruptured AAA 53 patients were symptomatic AAA (10% of the total 
study cohort). Sixty-one patients got fenestrated EVAR and 18 were branched repairs. The 
median number of components used was 3 (range 1-6) and the median introducer size was 20 
(range 11-24) for the ipsilateral side and 14 (range 11-14) for the contralateral side. In 
ruptured cases the median introducer size for the ipsilateral side was also 20 and the 
contralateral side was 16 (range 14-16). Median hospital length of stay was for non-rAAA 
patients 5 days (IQR=3) and for rAAA patients 9 days (IQR=11). 
In patients that underwent percutaneous EVAR (n=422/525, 81%), fascia suture technique 
was the most common method of primary femoral access site closure (n=263/422, 62%) 
followed by double ProStarXL® suture mediated femoral closure (n=159/422, 38%). One 
hundred and one patients (101/525, 19%) underwent primary open femoral access. 
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Five out of the 525 patients were converted to open AAA surgery.  
4.2.2 Perioperative bleeding related to preoperative and perioperative data 
Table 8 shows the bleeding volumes in elective, symptomatic and ruptured AAA cases. 
Table 8 Perioperative bleeding volume in non-ruptured and ruptured AAA 
Volume (ml) Elective          
n=382 
 
 
1000-1999 ml 
Symptomatic 
n=53 
Ruptured     
n=90 
Total            
n=525 
<1000 344 (90 %) 49 (93 %) 60 (67 %) 453(86 %) 
1000 – 1999 29 (8 %) 2 (4 %) 11 (12 %) 42 (8 %) 
2000 – 5000 8 (2 %) 1 (2 %) 10 (11%) 19 (4 %) 
>5000 1 (<0.5 %) 1 (2 %) 9 (10 %) 11 (2%) 
 
Table 9 Perioperative variables related to bleeding volume 
Bleeding volume (ml) 
 
< 1000 
(n=453) 
1000-
1999 
(n=42) 
2000-
5000 
(n=19) 
>5000 
(n=11) 
Total 
(n=525) 
 
P value 
Method of Access and Femoral closure    [523 (2 dead)] 
Open access* 60 20 10 11 101 
<0.001 Closure device* 
 
156 2 1 0 159 
Fascia Suture* 235 20 8 0 263 
Ruptured 60 11 10 9 90 <0.001 
Non ruptured 393 31 9 2 435 
Fenestrated (n) vs. standard 56 5 0 0 61 N/S 
Branched (n) vs. standard 11 5 2 0 18 <0.001 
Uni-iliac 13 0 4 1 18 <0.001 
Introducer size**† 19 22 22 22 20 <0.001 
Aneurysm diameter (mm) † 59 67 71 70 61 <0.001 
*Primary Method of Access Site Closure (n= 523 patients) Chi2 according to Monte Carlo method, 
**Ipsilateral side (median), †=Correlations according to Spearman. p-values refer to distribution differences 
across bleeding volume groups. 
Co-morbidity, anti-thrombotic medication or analyzed preoperative laboratory chemistry data 
was not significantly associated with increased perioperative bleeding.  
Open femoral access, fascia suture technique, branched or uni-iliac repair and aneurysm 
diameter were all associated with increased perioperative bleeding data presented in Table 9.  
4.2.3 Outcome related to perioperative bleeding 
The 30-day mortality for elective AAA treated by EVAR was 0.8%, for symptomatic 5.5% 
and for rAAA 21%.  
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4.2.3.1 Mortality related to perioperative bleeding 
Multivariable logistic regression analysis found that perioperative bleeding >2 liters was 
significantly associated with increased mortality in non-rAAA OR 30; 95% CI [3.6, 145] 
p=0.001 and rAAA patients OR 10.68; CI 95% [3.2, 36.1] p<0.001. Data from calculations of 
total cohort is presented in Table 10. 
Table 10 Univariable and multivariable analysis of factors influencing 30-day mortality total 
cohort 
Effect 
Univariable analysis Multivariable analysis 
OR 95 % CI P value OR 95 % CI P value 
Age > 80 y 2.8 1.2-6.6 0.02 - - N/S 
Pre-op S-Creatinine > 120 3.3 1.4-7.3 0.004 - - N/S 
Aneurysm diameter > 7 cm 4.8 2.0-11.8 0.001 - - N/S 
Rupture 19.1 7.4-49.6 <0.001 10.6 3.8-29.6 <0.001 
Bleeding > 2000 ml 30.8 12.2-77.4 <0.001 13.4 4.8-37.4 <0.001 
Non-significant data is not presented. N/S-non-significant. 
4.2.3.2 Morbidity related to perioperative bleeding 
In non-rAAA and rAAA patients (data analyzed separately) postoperative morbidity (renal 
failure, MOF, >5 days ICU, bowel ischemia and ACS) was analyzed in a multivariable 
logistic regression model and was found to be significantly associated with perioperative 
bleeding >2 liters (p<0.001). Tables 11 and 12 describe the complications in non-rAAA and 
rAAA patients. 
Table 11 Outcome related to intraoperative bleeding in EVAR patients with non-
ruptured Abdominal Aortic Aneurysms  
Bleeding volume ml (Total 
435) 
 
< 1000    
(393) 
1000-1999   
(31) 
2000-5000    
(9) 
>5000  
(2) 
Total 
 
P value 
Dead 30-days (n) 4 0 2 0 6 <0.001 
Renal failure (n) 7 0 1 2 10 <0.001 
MOF (n) 0 0 1 2 3 <0.001 
>5 days at ICU (n) 2 0 1 2 5 <0.001 
Bowel ischemia (n) 1 0 0 1 2 <0.001 
ACS (n) 1 0 0 2 3 <0.001 
EVAR=Endovascular Aneurysm Repair, MOF = Multi Organ Failure, ICU = Intensive Care Unit, ACS = 
Abdominal Compartment Syndrome. Chi2 according to Monte Carlo method. P-values refer across groups. 
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Table 12 Outcome related to intraoperative bleeding in EVAR patients with ruptured 
Abdominal Aortic Aneurysm 
Bleeding volume ml (Total 
90) 
 
< 1000      
(60) 
1000-1999    
(11) 
2000-5000  
(10) 
>5000      
(9) 
Total P value 
Dead 30-days (n) 6 2 5 6 19 <0.001 
Renal failure (n) 3 1 2 3 9 <0.001 
MOF (n) 4 1 1 4 10 <0.001 
>5 days at ICU (n) 5 1 2 4 12 <0.001 
Bowel ischemia (n) 3 0 2 2 7 <0.001 
ACS (n) 2 0 2 3 7 <0.001 
EVAR=Endovascular Aneurysm Repair, MOF = Multi Organ Failure, ICU = Intensive Care Unit, ACS = 
Abdominal Compartment Syndrome. Chi2 according to Monte Carlo method. P-values refer across groups. 
4.2.4 Discussion Paper II 
4.2.4.1 General comments 
Paper II evaluated the perioperative bleeding in EVAR and the associated outcome for non-
rAAA and rAAA. It is one of few previous studies that has evaluated outcome related to 
perioperative bleeding in acute and elective EVAR. Increased perioperative bleeding in open 
aortic surgery repair has been suggested as an independent risk factor for increased mortality 
and morbidity in previous studies but this has not been reported in EVAR before.1,2 
The findings suggest that measures should be taken to avoid large bleedings in order to 
reduce mortality and morbidity. The impact of antiplatelet medication on perioperative 
bleeding has not been evaluated. According to Paper II, 69% of non-ruptured AAA patients 
had ASA and 51% of the ruptured AAA.77 Only a few were on double treatment with 
Clopidogrel. The use of ASA is similar or more prevalent in both elective and ruptured 
patients in this study compared to other reports.82,205  
It seems motivated to perform a risk analysis of each patient undergoing EVAR in terms of 
potential bleeding complications.  
4.2.4.2 Outcome and perioperative bleeding 
Paper II includes the contemporary EVAR outcome experience from two centers with both 
conventional and more advanced reconstructions. 
4.2.4.2.1 Mortality and perioperative bleeding 
The presented 30–day mortality rates for elective and ruptured cases are comparable to 
previous studies.112,185 This study shows that perioperative bleeding is not an insignificant 
problem in EVAR. A strong correlation between bleeding >2 liters and 30-day mortality in 
both non-rAAA and rAAA patients was found. The few elective patients with blood loss 
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exceeding two liters limits conclusions about the impact on mortality of large bleedings in 
this group. 
The stronger correlation to mortality in multivariable analysis of perioperative bleeding >2 
liters compared to rupture, could possibly be explained by patients with a contained rupture. 
Without on-going bleeding and need of massive transfusions, it seems that rAAA patients 
often recover fast after endovascular repair. 
4.2.4.2.2 Morbidity and perioperative bleeding  
Postoperative complications were also strongly correlated to perioperative bleedings >2 liters 
in non-rAAA and rAAA patients. Elective patients with blood loss exceeding two liters 
showed a significant correlation to postoperative complications.  
4.2.4.3 Perioperative bleeding and preoperative and perioperative data 
The study suggests that perioperative blood loss is not associated with comorbidities or 
preoperative laboratory blood chemistry and coagulation data. It seems most often to be 
related to technical issues, such as open femoral artery approach and access sites closure 
problems.  
4.2.4.3.1 Preoperative bleeding and preoperative laboratory data  
In this study no significant association between comorbidities, preoperative laboratory data 
and perioperative bleeding were found. The preoperative chemistry data including Hb, 
Creatinine and PTr-INR were analyzed. No other coagulation tests than PTr-INR were 
analyzed. PTr-INR has in previous studies been suggested to be associated with large 
bleedings and worse outcome in rAAA patients.206 Although previously argued as a 
preoperative marker for developing coagulopathy and hampered outcome PTr-INR seems in 
this study not to be predictive for increased perioperative bleeding.  
4.2.4.3.2 Perioperative bleeding and access sites  
Technical factors were important and it seems preferable to avoid open femoral artery access 
and to use small introducer sizes to decrease perioperative bleeding. Preparedness for large 
perioperative bleeding is necessary in ruptured AAA cases, but also in advanced EVAR 
cases, such as branched EVAR. 
Open femoral access and closure by FST were associated with larger volumes of 
perioperative bleeding. It might be suggested that percutaneous EVAR should be advocated 
when possible in order to avoid unnecessary bleeding from the access sites. Patients 
undergoing FST bled more in this study. This is likely to be explained by the fact that more of 
the rAAA patients were found in this group. Direct percutaneous femoral puncture is usually 
preferred in rAAA patients with circulatory instability. FST for closure of the femoral arteries 
is then an attractive alternative as formal cut down and exposure of the arteries are avoided. 
No evaluation of the femoral plaque burden or subcutaneous fat layer was made in this study.  
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The safety of different methods of access site closure has previously been analysed.4-7,106 
Excellent results for closure device (double ProStarXL®) used off label for larger introducers 
sizes than 18 Fr, and fascia suture have been reported with failure rates of 2-10 %.105,106 In 
this study, fascia suture and closure device were equally successful. 
Large introducer sizes were also related to perioperative bleeding, which concurs with 
previous findings.5,107 Procedure time was not related to increased bleeding.  
Branched EVAR were also risk factors for increased perioperative bleeding this could 
possibly be explained by the use of large introducer sizes in these procedures. 
4.2.4.4 Limitations 
This study is limited by its retrospective nature. It is likely that a prospective study would 
provide a better material for evaluation.  
In patients undergoing EVAR for ruptured AAA, the internal blood volume loss is difficult to 
estimate. This is another limitation of this study. We based our estimation of the perioperative 
blood loss on established factors including blood-soaked lap sponges hemodynamic 
parameters and blood transfusion requirements. However, it is well known that, in surgical 
procedures in general, the perioperative estimated blood loss is both poorly reproducible and 
usually underestimated.152 In rAAA patients it may be possible to estimate the volume of the 
retroperitoneal or intra-abdominal hematoma using CT and 3D-volume rendering techniques, 
but this has not been established in AAA studies.207 The 3D-volume rendering techniques has 
previously been used in calculating volume of cerebral hematomas as a predictor for 
outcome.208 
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4.3 RESULTS AND DISCUSSION PAPER III  
This study analyzed preoperative coagulation data in relation to perioperative bleeding, 
hemodynamic status and outcome in patients undergoing repair for rAAA.  
4.3.1 Study cohort 
During the study period, 568 patients underwent treatment for AAA at our center including 
121 (21 %) patients with rAAA. Thirty rAAA patients were excluded from the analysis 
because of incomplete data. These patients did not differ from the study cohort in regards to 
demographics or outcome.  
The study cohort included 91 consecutive patients with rAAA (median age 74 years [range: 
57-91]; 80 % men) and complete preoperative laboratory data.  
Demographics, comorbidities and risk factors are presented in Table 13. There were no 
patients on warfarin or low molecular weight heparin.  
Table 13 Patient demographics and procedure related data 
 N=91 
Age (years) 74 y (57-91) 
Male 73 (80 %) 
  Comorbidities & risk factors 
COPD  18/85 (22 %) 
Diabetes 12/88 (14 %) 
Hypertension 59/85 (69 %) 
Heart disease 30/81 (37 %) 
Previous stroke 9/84 (11 %) 
Smoker*  31/53 (58 %) 
Aneurysm diameter 75 mm (IQR 29) 
EVAR 19 (21 %) 
Open repair 72 (79 %) 
Lowest preoperative BP 
(median)  
60 mmHg (IQR 40) 
Intraoperative bleeding  
<1999 ml 35 (39 %) 
2000-4999 ml 33 (36 %) 
>5000 ml 23 (25 %) 
 COPD=Chronic Obstructive Pulmonary Disease. *=On going or abstain 
<5 years ago. Percentages in brackets refer to distribution within each 
comorbidity/risk factor.  
Open surgical repair was performed in 72 patients (79 %) including straight tube grafts 
(n=46), aorto bi-iliac (n=22) and aortobifemoral (n=4). There were 19 (21 %) patients that 
underwent EVAR.  
Results and Discussion 
 
 61 
None of the EVARs were performed with fenestrated grafts. Resuscitative percutaneous 
balloon occlusion of the aorta (REBOA) was used in 5 EVAR and 5 open surgical cases. One 
patient with rAAA was previously treated with EVAR. 
4.3.2 Preoperative laboratory data 
Preoperative laboratory data in patients arriving in the emergency department with rAAA are 
presented in Table 14. There was no significant difference in laboratory data related to gender 
or comorbidities.  
Table 14 Preoperative laboratory data in patients (n=91) 
arriving in the emergency department with ruptured abdominal 
aortic aneurysm 
Test Median (IQR) Normal value  
Hemoglobin g/L 115 (IQR 36) 117-170 g/L 
APTT (s) 40 (IQR 19) 28-40 s 
Platelet count (109/L) 167 (IQR 104) 165-348 109/L 
P-Creatinine (µmol/L) 112 (IQR 48) <90 / <100 µmol/L 
PTr-INR 1.2 (IQR 0.5) <1,2 
Fibrinogen (g/L) 1,8 (IQR 1,4) 2,0-4,0 g/L 
IQR- interquartile range 
4.3.3 Preoperative coagulation data and blood pressure 
Preoperative fibrinogen and platelet concentrations showed linear relationships with 
preoperative blood pressure (BP) (r=0.477, p=0.01) and (r=0.247, p=0.05) respectively 
(Figures 13 and 14). The platelet correlation was not as strong as that of fibrinogen and BP. 
 
Figure 13
 
Figure 14
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Patients with a blood pressure <70 mmHg had a median fibrinogen concentration of 1.4 g/L 
(IQR 1.0) compared to patients with blood pressures ≥70 mmHg who had a median 
fibrinogen concentration of 2.5 g/L (IQR 1.9) (P= 0.001)(Figure 15). 
 
Figure 15. Box plot of preoperative fibrinogen and blood pressure 
 
4.3.4 Preoperative coagulation data and perioperative bleeding 
Preoperative fibrinogen concentration and platelet count were associated with perioperative 
bleeding. Lower preoperative fibrinogen concentrations and platelet counts were significantly 
associated with larger perioperative bleeding volumes. (P <0.001 and P = 0.024 respectively), 
data showed in Table 15.  
Table 15 Preoperative laboratory tests in relation to volume of intraoperative bleeding 
Bleeding volume ml (n)  < 1999 ml 
(n=29) 
2000-4999 m 
(n=26) 
>5000 ml 
(n=19) 
P-value 
Hemoglobin [g/L]  115 (IQR 37) 114 (IQR 32) 116 (IQR 39) n/s 
S-Creatinine (µmol/L) 106 (IQR 43) 113 (IQR 42) 120 (IQR 65) n/s 
PTr-INR 1,2 (IQR 0,2) 1,3 (IQR 0,7) 1,2 (IQR 0,4) n/s 
APTT (s) 37 (IQR 16) 44 (IQR 18) 42 (IQR 21) n/s 
Platelet count [109/L] 178 (IQR 95) 167 (IQR 118) 132 (IQR 99) 0,024 
Fibrinogen median g/L  2.3 (IQR 1.4) 1.6 (IQR 1.5) 1.4 (IQR 1.0) <0,001 
Median values (IQR=interquartile range), P-values across groups using Independent-Samples-Kruskal-Wallis 
Test 
In the multivariable logistic regression analysis (adjusting for the following statistically 
significant variables in the univariate analysis: age >80 years, Creatinine >120 µmol/L, 
blood pressure <70 mmHg, fibrinogen <1.5 g/L, and previous stroke), fibrinogen <1.5 g/L 
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OR 10.04; 95% CI [1.8, 57.1], (P = 0.009) and blood pressure <70 mmHg OR 3.7; 95% CI 
[1.1, 12.5], (P = 0,034) were associated with IOB >2000 ml.  
A preoperative blood pressure below 70 mmHg was also associated with large IOB >5000 
ml OR 5.2; 95% CI [1.3, 21.1], (P = 0.021).  
4.3.5 Preoperative coagulation data and outcome 
The total 30-day mortality was 33 % (30/91; open repair 37.5% 27/72; 15.8% EVAR 3/19). 
Table 16 shows the difference in preoperative variables for the two repair techniques. Other 
preoperative laboratory variables were not significantly different between the repair 
techniques.  
Table 16 Preoperative variables and method of repair 
 Open repair EVAR p value 
Fibrinogen median (g/L) 1.7 (IQR 1.3) 2.3 (IQR 1.3) p = 0.014 
Platelets median (109/L) 162 (IQR 107) 183 (IQR 132) p = 0.011 
Preoperative blood pressure 
(mean) (mmHg) 61 (SD 34) 91 (SD 39) p = 0.001 
 
Postoperative complications among 30-day survivors included MOF (22%), ACS (17%), 
relaparotomy for bleeding (11%), bowel ischemia (13%), MI and stroke (2% respectively).  
Low fibrinogen concentration (<1.5 g/L), elevated s-Creatinine (>120 µmol/L), low blood 
pressure (<70 mmHg), previous stroke, and perioperative bleeding >5000 ml were all 
associated with 30-day mortality in the univariate analysis. In the multivariable logistic 
regression analysis only previous cerebrovascular events OR 15.91; 95% CI [2.2, 115.07], (p 
= 0.006) and IOB >5000 ml OR 4.89; 95% CI [1.23, 19.46], (p = 0.024) were significantly 
associated with mortality (fibrinogen concentration <1.5 g/L OR 1.49; 95% CI [0.35, 6.29], 
(p = 0.59). 
4.3.6 Discussion Paper III 
4.3.6.1 General comments 
In Paper III the association between preoperative coagulation tests, hemodynamic status, 
perioperative bleeding and outcome were analyzed in patients undergoing repair for rAAA. 
Low preoperative fibrinogen and platelet concentrations were significantly associated with 
preoperative hypotension and increased IOB in patients with rAAA.  Extensive hemorrhage 
in rAAA is associated with high mortality and immediate measures should be taken to limit 
the blood loss and correct coagulopathy. 
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By finding early predictors for critical bleeding direct proactive measures could be taken.  
The development of coagulopathy in patients with rAAA has been described in previous 
studies170-172. It is one of the strongest predictors of poor outcome and it is vital to detect it 
early.170,209 
The role of fibrinogen has gained increasing focus in the risk analysis of perioperative 
bleedings and coagulopathy in trauma, orthopedics and in the cardiovascular literature.210,211 
Fibrinogen has been suggested for early proactive use in severely bleeding aortic aneurysm 
patients, as well as in trauma and cardiac bypass patients.212-215  
The overall mortality and morbidity outcome was comparable to that of other studies. EVAR 
was associated with a better outcome. However, selection bias in method of repair was 
suspected since preoperative blood pressure, fibrinogen and platelet concentration differed 
significantly between the OR repaired patients and EVAR patients. 
4.3.6.2 Fibrinogen and rAAA 
Fibrinogen acts as one of the key factors in the coagulation cascade by being transformed into 
fibrin through the help of thrombin. Its’ function and contribution in hemostasis is more 
precisely described in the Introduction, Section 1.4.2.2.  
According to literature review only one previous study has analyzed preoperative fibrinogen 
in rAAA patients.173 In Study III, it was observed that patients presenting with hemodynamic 
shock with a blood pressure <70 mmHg, had an associated median fibrinogen concentration 
of less than 1.5 g/L. Fibrinogen deficiency in rAAA is believed to occur due to extensive 
blood loss and consumption of clotting factors. In addition, activation of the fibrinolytic 
system, acidosis, hypothermia, and metabolic changes also affect fibrinogen polymerization 
and metabolism.216 It has been shown that rAAA activates anti-inflammatory processes.217 It 
is possible that these processes affect fibrinogen concentration. During major hemorrhage 
there are indications that fibrinogen reaches a critical threshold earlier than other 
procoagulatory factors or platelets. 
Preoperative fibrinogen values (<2 g/L) were observed in patients with >2000 ml 
perioperative bleeding. A fibrinogen concentration of less than 1.5 g/L was independently 
associated with intraoperative blood loss of more than 2000 ml in the logistic regression 
analysis. Preoperative fibrinogen <1.5 g/L was in univariable analysis significantly associated 
to increased mortality rate. In multivariable logistic regression no significant correlation was 
seen. The difference in preoperative values of fibrinogen and platelets between the two 
operative methods imply a difference in selection for the repair methods with more severely 
hypotensive patients in the OR group. 
The Clauss method is the most common method of measuring fibrinogen concentration and 
was used in this study.218 The test is based on the time for fibrin clot formation by adding an 
excess amount of thrombin to a centrifuged plasma sample and thereby activating the 
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fibrinogen into a fibrin clot. Emergency laboratories can normally present a result within 30 
minutes.  
Fibrinogen concentration and function can be estimated through viscoelastic tests (TEG and 
ROTEM). These tests are promoted as quicker (approximately 15 minutes) and assess many 
parts of the coagulation. They have in previous studies shown promising and interesting 
results in both trauma and elective vascular patients.219,220 The clinical value in patients with 
rAAA is yet to be evaluated.  
4.3.6.3 Platelets and rAAA 
Platelets are an essential part of hemostasis. Their function is described in more detail in 
Introduction, Section 1.4.2.1. In large bleeding they are consumed and their advanced 
functions can be hampered by a number of factors. It is of essence to have enough platelets in 
the blood volume in order for the blood still to be able to clot. The exact threshold for when 
to transfuse platelets varies. Standard laboratory platelet count estimates the platelet number 
or concentration in the blood. The method does not reflect the quality of platelet function. 
Previous investigation about platelet consumption in rAAA patients has shown a significant 
correlation between low platelet count (<150 109/L) on admission and mortality.221 Suggested 
threshold values for platelet concentration (125-400 109/L) are probably not correct for this 
patient category. 
Decreased platelet counts were associated with increased perioperative bleeding. The 
preoperative platelet concentrations were however not below 100 109/L even in patients that 
had perioperative bleeding volumes >5000 ml. Lower platelet concentration was also 
significantly associated with preoperative hypotension. It can be argued that the observed 
decrease in platelet concentration is of clinical insignificance. It could also represent a 
stronger resilience of the platelet concentration to hypotensive hemodynamic status in rAAA 
patients or that platelet concentration measurement is not specific enough to detect early 
deviations in platelet function and concentration.  
Evaluation of point-of-care tests should be a natural path forward to gain deeper knowledge. 
In future these tests might be important in patients with rAAA.  
4.3.6.4 Limitations 
Paper III was a retrospective study and limitations apply. The cohort was contemporary and 
consecutive. The outcome analysis did not separate the operative methods (OR/EVAR). A 
larger cohort would make it possible to perform further subgroup analysis. A selection bias 
when choosing operative method is likely. It was difficult to evaluate the exact time for the 
preoperative laboratory tests in relation to the rupture and patient arrival in in the emergency 
department. Blood samples in all patients were stated as preoperative in the medical records 
and laboratory database. A few patients might have started transfusions in close conjunction 
to the first laboratory tests. Preoperative fluid resuscitation was managed through permissive 
hypotension and crystalloids were only given in small boluses according to local protocol. 
The volumes of crystalloids given were difficult to evaluate.  
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4.4 RESULTS AND DISCUSSION PAPER IV 
In Paper IV massive transfusion in patients with rAAA was analyzed. 
4.4.1 Study cohort  
During the study period a total of 406 patients underwent rAAA repair at the enrolled centers. 
Twenty-nine of these patients were excluded due to failure to match with the transfusion 
registry and 8 patients lacked transfusion data. A total of 369 rAAA patients undergoing 
repair was included. Demographics and comorbidities are presented in Table 17. 173 (47 %) 
EVAR and 196 (53 %) OR were performed with median RBC transfusion 8 u (IQR 4-14) and 
14 u (IQR 8-28), respectively. 
Table 17 Demographics and comorbidities 
 Massive 
transfusion 
(n=261) 
rAAA without        
massive transfusion 
(n=108) 
Patients treated  
with EVAR  
(n=173) 
Patients treated           
with open surgery 
(n=196) 
Age 76 (70-82) a 78 (71-82) a 77 (72-83) a 76 (69-81) a 
Male 212 (81%) 85 (79%) 136 (79%) 161 (82%) 
Hypertensionb 146 (78%) 51 (65%) 78 (70%) 119 (76%) 
COPDc 48 (30%) 14 (20%) 27 (30%) 35 (26%) 
Heart Riskd 83 (45%) 22 (30%) 45 (42%) 60 (39%) 
Diabetese 30 (15%) 17 (20%) 24 (20%) 23 (14%) 
Previous strokef 35 (21%) 10 (15%) 14 (17%) 31 (20%) 
RBC transfusion 13 (8-23) 2 (2-4) 6 (3-11) 12 (7-23) 
a Median (25th percentile, 75th percentile), b Data missing for 28% of patients, c COPD=Chronic Obstructive Pulmonary Disease, Data missing 
for 38% of patients, d Data missing for 30% of patients, e Data missing for 22% of patients, f Data missing for 37% of patients, rAAA=ruptured 
Abdominal Aortic Aneurysm, EVAR=Endovascular Aortic Repair 
4.4.2 Overall blood transfusions 
In Table 18, the overall transfusion data in massively transfused patients (n=261; 71%) and 
patients that did not require massive transfusion (MT) (n=108; 29%) are presented. EVAR 
patients with MT (n=96) required significantly less blood transfusion compared to patients 
undergoing OR (n=165) (p<0.001, median test).  
Table 18 Transfusion data and FFP:RBC PLT:RBC ratios in MT and non-MT patients 
 Massively 
transfused EVAR 
(n=96) 
Massively transfused 
open surgery (n=165) 
Non-massively 
transfused 
EVAR (n=77) 
Non-massively transfused 
open surgery (n=31) 
RBC 10 (6-16.5) 15 (9-26) 3 (2-4) 2 (2-3) 
Plasma 6 (2-14.5) 13 (7-24) 0 (0-1) 2 (0-5) 
Platelets 0 (0-2) 2 (0-4) 0 (0-0) 0 (0-1) 
FFP:RBC 0.59 (0.33-0.86) 0.84 (0.67-1.02) 0 (0-0.25) 0.67 (0.33-1.33) 
Platelets:RBC 0 (0-0.17) 0.12 (0-0.18) 0 (0-0) 0 (0-0.22) 
Values presented as median and inter quartile range (IQR=25th-75th percentile) RBC=Red Blood Cells, FFP=Fresh Frozen 
Plasma, PLT=Platelets 
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4.4.3 Ratios of FFP:RBC and PLT:RBC in massively transfused patients 
The correlation between transfused FFP and RBC was significant p<0.001 as demonstrated 
by Figure 16.  For all patients the median blood product ratios were 0.67 (IQR: 0.28-1) for 
FFP:RBC and 0.03 (IQR: 0-0.16) for PLT:RBC. Median blood product ratios for FFP:RBC 
were: for EVAR 0.59 (IQR: 0.33-0.86) and OR 0.84 (IQR: 0.67-1.2); p<0.001].  
 
 
 
 
 
Figure 16 Relationship FFP:RBC in all rAAA patients. Plotted overall ratio of units of fresh frozen plasma 
against units of packed red blood cells, calculated after the first 24 hours from first order of any blood product. 
 
 
 
 
Figure 17. Relationship PLT:RBC in all rAAA patients. Plotted overall ratio of units of and units of platelets 
against units of packed red blood cells, calculated after the first 24 hours from first order of any blood product. 
The transfused ratio of PLT:RBC in the whole group was 0.14 as demonstrated by Figure 17. 
The relationship between transfused PLT and RBC was significant p=0.024.  
There was a significant difference in ratios between patients repaired with EVAR and open 
surgery PLT:RBC ratio EVAR 0 (IQR: 0-0.17) and for the OR group 0.12 (IQR: 0-0.18); 
p<0.001. 
4.4.4 Time dependent ratios and timing of ordering blood products 
For patients requiring MT the blood product ratios increased over the studied 24 h after the 
first transfusion order. Figure 18 plots the changing ratios over time. Both FFP:RBC and 
PLT:RBC ratios showed to be very low in the early hours to consequently increase to a 
steady ratio after about 2.5 hours. 
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Figure 18. Relationship FFP:RBC and PLT:RBC in all rAAA patients. The curves represents the changes in 
ratios of [plasma/red blood cells] and [platelets/red blood cells] for massively transfused patients plotted 
against time (h) during the first 24 hours after the first orders of blood transfusion.  
4.4.5 Ratios and time of first transfusion of FFP and PLT related to 
outcome 
The FFP:RBC ratio was associated with 30-day mortality in patients undergoing open repair 
as shown in Figure 19. As the ratio approached 1 the risk for mortality was reduced 
(p=0.003, logistic regression adjusted for age and total amount of transfusion). The same 
relationship was not seen in patients undergoing EVAR. 
 
Figure 19. Predicted risk of mortality against ratio units of fresh frozen plasma to units of red blood cells for 
patients undergoing open repair. Horizontal boxplot plotted above curve to show distribution. Curve adjusted 
for the average values of age and total transfusion in the massively transfused open repair group. 
No significant association between PLT:RBC ratio and 30-day mortality was seen. 
Delayed PLT transfusion in patients undergoing open repair or EVAR was associated with 
30-day mortality as shown in Figures 20 and 21. Transfusion of platelets (compared to no 
transfusion) was also significantly associated with increased risk for OR patients, odds ratio 
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2.93; 95% CI [1.04, 8.23] but not for EVAR patients, odds ratio 2.05; 95% CI [0.55-7.58]. A 
similar relationship could not be shown for time of first FFP and 30-day mortality as the vast 
majority of patients got plasma very early. 
 
Figure 20. The predicted risk of mortality plotted as a curve against time (h) until transfusion of platelets in open 
repaired patients. Horizontal boxplot of distribution plotted above curve. Odds ratio calculated by logistic 
regression (adjusted for age) OR: P=0.012.  Curves adjusted for the average values of age. 
 
Figure 21. The predicted risk of mortality plotted as a curve against time (h) until transfusion of platelets in 
patients undergoing EVAR. Horizontal boxplot of distribution plotted above curve. Odds ratio calculated by 
logistic regression (adjusted for age) EVAR: P=0.003.  Curves adjusted for the average values of age. 
4.4.6 Hemodynamic status and blood transfusion 
The lowest preoperative systolic blood pressure was inversely correlated to the number of 
total units RBC received as presented in Figure 22.  
Patients presenting severely hypotensive received earlier transfusion of FFP and PLT than 
normotensive patients. 
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Figure 22. Lowest preoperative systolic blood pressure (mmHg) vs. total amount of units of packed red blood 
cells given. 
4.4.7 Changes in transfusion ratios over the course of the study 
Over the study-period, median PLT:RBC ratio increased significantly in massively transfused 
patients, as demonstrated in Figure 23 (p<0.001, median test). The median PLT:RBC ratio 
for 2008-2010 was 0.07 while the median PLT:RBC ratio for 2011-2013 was 0.14. The same 
trend was not seen for FFP:RBC ratio (p=0.10, median test).  
 
 
 
 
 
Figure 23. The 24 h ratios of units of 
platelets/units of packed red blood cells in 
massively transfused patients plotted against 
time (dates) during the study period. 
4.4.8 Discussion Paper IV  
4.4.8.1 General comments 
In Paper IV the effect of blood transfusion and blood product ratios on outcomes in rAAA 
patients were analyzed. Seventy one percent of all patients undergoing rAAA repair required 
massive transfusion and more than half of the patients undergoing EVAR required massive 
blood transfusion. The overall transfusion requirements were lower in the EVAR group 
compared to open surgery. The ratios of FFP:RBC and PLT:RBC were significantly lower in 
the EVAR group. A FFP:RBC ratio close to one was associated with a lower risk for 
mortality. A significant survival advantage was suggested in patients receiving early PLT 
transfusion.  
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4.4.8.2 Transfusion in rAAA patients 
A lower than expected PLT:RBC ratio in both open repaired and EVAR patients was found. 
Also a delay in the transfusion of PLT was observed. This diverts from the massive 
transfusion guidelines adopted at the enrolled centers. The massive transfusion protocols 
suggest transfusion in ratios 1:1:1 and early transfusion of platelets. Universal donor blood in 
packages of 4 U RBC and 4 U FFP are usually available at the emergency departments at the 
enrolled centers. In rAAA patients with hemodynamic impairment these emergency packs (at 
some centers referred to as “trauma packs”) are entered into the transfusion registries a 
posteriori. A previous study has controlled this retrospective method to be accurate both in 
timing and in amounts of units.222  
A later platelet transfusion is likely to be attributed to both the fact that no emergency PLT 
units are available at the ED and the fact that the threshold for PLT transfusion of platelet 
count of <50 109/L seldom is reached preoperatively in rAAA patients.169 Another possible 
reason for delaying platelet replacement in aortic repair may be the possible risk of 
perioperative thrombosis. Also coagulopathy may be more difficult to diagnose in EVAR 
patients, which might explain the lower than recommended ratios of both FFP and PLT in 
this group. Perioperative point of care tests, i.e. thromboelastography, may be helpful to 
diagnose coagulopathy and tailor the hemostatic resuscitation. 
Our results that transfusion ratios of FFP:RBC that approach 1:1 lower risk of mortality, 
concurs with previous findings. PLT:RBC ratios were not significantly associated with 
mortality in this study. It was noted that a few patients with extremely high ratios of 
PLT:RBC had higher mortality, this observation is likely to be explained by the fact that 
these patients suffered from surgically uncontrollable bleedings (and that platelets given were 
insufficient for controlling the bleeding and reversing the coagulopathy). 
It might be reasonable to argue that the transfusion recommendations should differ between 
patients treated with EVAR compared to open repair given the different nature of the two 
methods of repair. Even though EVAR patients received smaller volumes of transfusion with 
lower FFP:RBC and PLT:RBC ratios compared to open repaired patients, a majority (55 %) 
required massive transfusion. This finding justifies further studies on transfusion strategies 
and management of coagulopathy in rAAA patients undergoing EVAR.  
PLT:RBC ratio increased over the study period. The same observation was not seen for 
FFP:RBC ratio. This might be explained by that more aggressive and early transfusion of 
platelets in patients requiring MT has gained focus in recent literature. A general shift of 
improvement in bedside monitoring of coagulopathy and hemodynamic status might also 
contribute to this observation. 
4.4.8.3 Limitations 
This study carries limitations due to its retrospective design and the registries used for data 
collection. The data analyzed is retrieved from large registries, which might skew data and 
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must be taken into consideration when interpreting the results.  The transfusion registry has 
previously been validated and shows accuracy regarding transfusion time and volume.222 A 
variation in transfusion regimes in between individual anesthesiologists is likely. However, 
we believe the generalizability of data is satisfying considering inclusion of three large 
hospitals.   
In order to better provide recommendations for optimal transfusion ratios and timing of blood 
products in treatment for rAAA, especially endovascular repair, prospective randomized trials 
may be needed.   
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5 GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
The overall aim of this thesis was to investigate different aspects of perioperative bleeding in 
patients undergoing open or endovascular repair for AAA. The perioperative management of 
patients with massive bleeding has been refined through increased knowledge in hemostasis 
surveillance, new methods for coagulation testing and therapeutics as well as in the field of 
transfusion and critical care. Extensive knowledge has especially sprung from the trauma 
literature. In vascular surgery there is still a need and opportunity for further investigation. 
The embarked endovascular treatment era of AAA offers a minimally invasive method 
associated with decreased perioperative blood loss compared to open repair. This fact is a 
welcome progress for the patients awaiting repair of their diagnosed or undiagnosed AAAs. It 
justifies one of the preface questions; -Should really more time be invested in scientific 
research about perioperative bleeding in AAA repair. Bleeding poses a potential life-
threatening condition for the rAAA patient undergoing repair also by EVAR, and yes there is 
a need for further investigation in patients with critical bleeding. Papers II, III and IV 
supports these statements. 
It is clear from the included studies that outcome after AAA repair cannot only be measured 
in mortality. In Papers II and IV increased perioperative bleeding was significantly associated 
with increased morbidity. Morbidity measures can be questioned from registry studies as 
registry users might refrain from report and hence skew data to a more attractive heritage of 
the individual surgical doings. Mortality cannot be hidden in registry data but complications 
and suffering can. However there are ways to tackle this by letting professional registry 
administrators enter the data and by automated data retrieval from medical records. In 
pursuing further knowledge about the impact of perioperative bleeding proper and robust 
methods of detecting postoperative complications must be applied. A form of self-reporting 
through web-based surveys is probably one possible path to explore. 
EVAR is a “tool intense” treatment option with high costs for the materials used. In the 
introduction it was described that previous literature supports the percutaneous access 
approach to EVAR instead of surgical cut down to the femoral arteries as it offers less 
complications and a faster procedure. Paper I studies and suggests the safe use of the fascia 
suture technique (FST). It can be used as an alternative to pricy closure devices for 
hemostasis in the femoral access sites. Other studies also supports the FST as safe but still its 
use is not routine practice at many centers.203 A considerable amount of money would saved 
in material costs on a yearly basis if all femoral access sites after EVAR would be closed by 
FST instead of all closed by ProStarXL®. A prospective randomized trial has recently been 
published, but additional investigations will be needed in order to verify that the results are 
reproducible.204 
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It is difficult to estimate the volume of bleeding correctly. Much of the bleeding volume data 
used in this thesis project relies on registry data. In the Swedvasc registry the estimated 
volumes are categorized by predetermined groups of bleeding volume. A better way would 
be if the estimated volumes reported into the registry were entered as a summed numeral in 
milliliters. In Paper II one of the aims was to find a cut off value for when bleeding starts to 
be critical. A volume of above 2000 ml seems to related to increased risk for complications. 
Estimation methods for measuring blood loss need further evaluation. In the case of rAAA 
undergoing EVAR the preoperative bleeding cannot be evaluated through visualization and 
measurement through suction and surgical gauzes. An evaluation of the preoperative volume 
by computer tomography 3D volume rendering could be an alternative for estimation to 
explore. 
Preoperative predictors for increased perioperative bleeding were studied in Paper III. 
Fibrinogen and platelet count were affected early by hemodynamic instability and more 
attention should be paid to these laboratory tests than previously have been described. The 
preoperative value (PTr-INR >1.2) was not significantly associated to perioperative bleeding 
in this cohort. Others have suggested this to be a marker for coagulopathy. Trauma patients 
arriving with a PTr-INR >1.2 had significantly higher mortality and transfusion requirements 
than patients with a normal PTr-INR.146 Also severe APTT prolongations >1.8 times normal 
have been associated with bleeding but seems to be less sensitive than PTr-INR.223,224 
Fibrinogen concentrations might add important value as a preoperative test, also in non-
ruptured AAA, as it was found to be more sensitive than the other coagulation tests. This 
concurs with findings in previous studies analyzing blood loss and fibrinogen.210,225,226 
Additional studies are needed in vascular surgery and AAA repair in particular. 
Paper III suggests that rAAA patients with severe hypotension potentially could benefit from 
early administration of fibrinogen concentrates. This hypothesis certainly needs to be 
evaluated in prospective randomized clinical trials. Hemostatic therapy with fibrinogen 
concentrate in patients undergoing elective major aortic surgery at a single-center has 
significantly reduced the transfusion of blood products.227 In guidelines for management of 
bleeding following major trauma, treatment with fibrinogen concentrate is recommended if 
significant bleeding is accompanied by thromboelastometric signs of a functional fibrinogen 
deficit or a plasma fibrinogen level of less than 1.5-2.0 g/l.190 However, a recent Cochrane 
review by Wikkelso et al. investigated the evidence for the use of fibrinogen concentrate in 
bleeding patients and stated that evidence is sparse and randomized controlled studies are 
lacking.16 It is also important to address if there is an associated delayed risk of thrombosis 
after use of fibrinogen concentrate. In rAAA the use of fibrinogen concentrate should be 
further evaluated.213 Prospective randomized trials, as suggested above, could answer some of 
these questions.  
The overall perfect hemostasis measurement method is still not available. Most centers use 
standard coagulation tests in clinical practice, even though these tests were not developed to 
guide coagulation management in the emergency surgical situation.224 In Paper III the 
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commonly used laboratory markers were investigated in relation to blood pressure and 
outcome in rAAA. Viscoelastic testing is on the rise and studies are performed especially in 
the field of trauma. Exciting and promising data have originated from clinical evaluations of 
the tests in various fields of medical practice.228 However, the methods have limitations. In all 
known coagulation testing, blood is removed from the patient and the total functionality 
cannot yet be tested on site in the blood vessels. A future goal is to transfer the methods of 
evaluation and treatment into the site of action, and by expeditious methods instantly be able 
to diagnose, correct and treat an impaired hemostatic process. Spray pulses of concentrated 
coagulation factors where best needed in the body through injections by needles, LRTs and/or 
catheters might be possible treatment options to explore. 
Patients undergoing AAA repair are often subject to blood transfusion. It is by now well 
described that the ratios between blood products influence outcome in other surgical fields. 
The comorbidities and severity of the AAA disease offer special considerations when 
transfusing these patients massively. A goal driven transfusion strategy would probably best 
suit this patient cohort and a practice of arbitrary transfusion of blood products should be 
avoided. The rapid start of transfusing platelets in massively bleeding patients seems to affect 
the outcome (Paper IV) in rAAA patients. This raises questions of early detection of the 
potential need to do so and if this can be accomplished by better routines and increased 
awareness. Quick off the shelf supply is only available to a limited extent. In order to further 
explore this key topic, prospective data collection and future randomized controlled trials are 
required.  
Vascular surgeons are regularly engaged as specialists in controlling surgical bleedings in 
different parts of the body and not only in relation to vascular diseases and vascular surgery 
complications and iatrogenic vascular injuries. Vascular surgeons are also often used as 
advisors in thromboembolic events in arteries as well as in veins. The management of 
bleeding, coagulopathy and thrombosis is a moving target where the development over the 
last years challenges old truths and physicians to keep updated. In order to meet the 
expectations from patients and colleagues the vascular surgeon must be equipped with the 
adequate knowledge and a powerful armament to fight bleeding. Above all the vascular 
surgeon needs to embrace the motto of Sir Robert Baden Powel and the Scout movement:  
-Be prepared! 
-Always prepared! 
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6 CONCLUSIONS 
 
• The fascia suture technique was shown to be a safe, effective, and simple method to 
gain hemostasis at the femoral access sites after EVAR. It was effective also after 
large diameter introducers up to 24 Fr. No specific preoperative risk factor for the 
failure of fascia suture technique was found. It was deemed as a valid alternative to 
other techniques of obtaining postoperative hemostasis and has economic advantages. 
• Large perioperative hemorrhage during EVAR was found to be a clinical problem 
that affects outcome. Efforts must be made to minimize perioperative blood loss.  
• A perioperative blood loss exceeding 2 liters was independently associated with 
increased mortality and morbidity in both acute and elective AAA patients. Open 
femoral access, branched EVAR and larger diameter introducers were associated with 
increased perioperative blood loss.   
• Low preoperative fibrinogen concentration was significantly associated with 
preoperative hypotension and increased perioperative bleeding. 
Hypofibrinogenemia should be suspected in preoperative hypotension (<70mmHg).  
• Preoperative fibrinogen concentrations below 1.5 g/L were associated with a ten-
fold increased risk of perioperative bleeding of more than 2 liters. Future studies 
need to investigate the potential benefit of early treatment with fibrinogen 
concentrate in patients with rAAA and hemodynamic shock. 
• In massively transfused rAAA patients, EVAR was associated with smaller 
transfusion volumes and with lower FFP:RBC and PLT:RBC ratios compared to open 
repair. More than half of rAAA patients repaired by EVAR required massive 
transfusion. 
• Lower risk of mortality was seen in patients with FFP:RBC ratios of close to 1:1 in 
EVAR and open repaired AAA patients.  
• Delayed (>1h) platelet transfusion in patients with rAAA requiring massive 
transfusion was associated with significantly increased mortality.  
• Ratios of PLT:RBC have increased over the last years. Transfusion strategies, in 
patients undergoing rAAA treatment with EVAR or open repair, need further 
research.  
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7 SAMMANFATTNING PÅ SVENSKA 
Avhandlingens bakgrund och syfte: 
Det övergripande syftet med avhandlingen var att studera olika aspekter av 
blödningsproblematik vid behandling av bukaortaaneurysm (BAA), på engelska abdominal 
aortic aneurysm (AAA).  
Blödning vid operation av AAA kan vara betydande. Vid minimalinvasiv endovaskulär 
behandling (endovascular aortic aneurysm repair, EVAR) behandlas den sjuka 
kroppspulsådern med ett så kallad stentgraft som placeras på insidan av kroppspulsådern, ofta 
med mindre blödningsproblematik jämfört med öppen kirurgi. Det är känt att blödning i 
samband med operation påverkar resultatet, men få studier har undersökt problemen 
relaterade till blödning vid behandling av AAA. För EVAR finns relativt få studier som 
analyserar just blödningsproblematik. 
Blödning under ingreppet, prediktiva markörer och blodtransfusion vid öppen kirurgi och 
EVAR studerades i fyra olika studier. Både planerade och akuta behandlingar av AAA 
undersöktes.  
Det specifika syftet med studierna var: 
• Att undersöka användbarhet, säkerhet, resultat och eventuella faktorer som påverkar 
utfallet vid användning av en särskild operationsteknik för blödningskontroll i 
ljumskpulsådern efter EVAR. Operationstekniken kallas Fascia Suture Technique och 
förkortas FST. 
• Att studera blödingsvolym och dess relation till resultat vid EVAR vad gäller både 
akuta och planerade ingrepp. 
• Att studera laboratorieprover avseende blodets förmåga att levra sig, tagna före 
operation, hos patienter med brustet AAA samt att relatera dessa till resultat och 
patientens blodtryck före behandling. 
• Att studera förhållandet mellan givna blodtransfusioner och resultat vid brustna AAA 
hos patienter som genomgår EVAR eller öppen kirurgi. Vi studerade tidsaspekter och 
förhållanden mellan antal enheter av röda blodkroppar, plasma och blodplättar 
(trombocyter) som givits. 
Patienter och metoder: 
Samtliga studier var retrospektiva och baserades på patientjournaler samt regionala och 
nationella register (Studie II-IV). I Studie I undersöktes 160 FST som operativ 
förslutningsmetod för blödningskontroll av ljumskkärlsinfart efter EVAR. Vi granskade 
datortomografibilder tagna före och ett år efter operation. Studie II analyserade brustna och 
icke-brustna AAA bland 525 patienter som genomgick antingen öppen eller endovaskulär 
behandling. Korrelationen mellan blödning under operationen och mortalitet och morbiditet 
undersöktes. I Studie III undersöktes 91 patienter med brustna AAA avseende 
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laboratorieanalyser av blodets förmåga att levra sig och deras förhållande till lågt blodtryck 
före operation, blödningsvolym och komplikationer. I Studie IV undersöktes blodtransfusion 
av 369 patienter med brustet AAA som genomgått öppen eller endovaskulär behandling. 
Tidpunkt för blodtransfusion och tidsberoende förhållanden av givna blodprodukter 
studerades och relaterades till metod för kirurgisk behandling och resultat. Olika statistiska 
metoder användes för att utvärdera eventuella samband. 
Resultat: 
Studie I visade att 91 % av FST utfördes med lyckat resultat. Få komplikationer uppstod och 
inga tydliga riskfaktorer för negativt utfall av metoden hittades. I Studie II fann man att en 
blödning av >2 liter under ingreppet var oberoende relaterat till ökad dödlighet och 
komplikationer (njurskada, multiorgansvikt, >5 dagar på intensivvårdsavdelning, bristande 
blodflöde till tarmen samt ökat buktryck) bland planerade och brustna AAA. I Studie III 
visades att lågt fibrinogen värde (<1.5 g/L) i plasma var associerat med lågt blodtryck 
(systoliskt blodtryck <70 mmHg), ökad blödning och sämre resultat. Studie IV visade att 
fördröjd trombocyttransfusion (>1h) var associerad med ökad dödlighet hos patienter med 
brustna AAA som krävde massiv transfusion (>10 enheter röda blodkroppar (RBC) inom 24 
timmar eller 4 enheter RBC inom en timme). Transfusionsförhållandet av kvoten 1:1 mellan 
given färskfrusen plasma (FFP) i förhållande till RBC var associerat med lägre dödlighet. 
Förhållandet mellan givna trombocytkoncentrat (PLT) och RBC ökade under studieperioden. 
Slutsatser: 
• Fascia Suture Technique visade sig vara en enkel och säker teknik med ett lågt antal 
komplikationer. Inga preoperativa riskfaktorer identifierades. 
• En blodförlust större än två liter vid operation med EVAR viades ha ett oberoende 
samband med ökad dödlighet och sjuklighet vid både akuta och planerade AAA 
ingrepp. Öppen operation för åtkomst av ljumskkärl, grenade EVAR och större 
diameter av införingsinstrument var relaterat till ökad blodförlust. 
• Hos patienter med fibrinogenkoncentrationer mindre än 1,5 g/L före operation förelåg 
en tio-faldigt ökad risk för intraoperativ blödning på mer än 2 liter vid brustna AAA. 
Lågt fibrinogen skall misstänkas vid lågt blodtryck (<70mmHg) vid brustna AAA. 
• Massiv transfusion erfodrades bland 55 % av patienter med brustna AAA behandlade 
med EVAR. Ett kvotförhållande mellan FFP och RBC nära 1:1 vid såväl EVAR som 
öppet opererade patienter var förenat med lägre dödlighet. 
• Fördröjd (>1h) transfusion av trombocytkoncentrat var förenat med signifikant ökad 
dödlighet. Transfusionskvotförhållandet mellan PLT och RBC ökade under 
studietiden. 
• Transfusionsstrategier hos patienter som genomgår behandling med EVAR eller 
öppen behandling efter brustet AAA, kräver ytterligare forskning. Användning av 
fibrinogenkoncentrat hos patienter med brustet AAA och lågt blodtryck behöver 
ytterligare utredas. 
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